Podcasts about MDMA

“Psychedelics trigger a unitive state, and meditation trains it.”So says Naina Eira Gupta, who researches the therapeutic potential of psychedelics and meditation.Psychedelics work because they disrupt the monkey mind, she asserts. They stop the constant chattering in your head, which is the mind's MO to perpetuate the story of ‘you'.Everything we think we have is just that, a story.“Psychedelics are assisted mind training, I would call it. They provide mental immunity”, says Naina.Then, meditation trains you to keep that base perception, to see the story for what it is.“You realize you don't have to be reactive to a particular thought or feeling, because it's just a story.“When the ego dissolves, you become so much more of an effective human being.“You can fall in love with the world. Everything becomes lighter. You don't feel so much distance between what you perceive as ‘you' and the rest of it.”What Naina hopes for is that more people have access to mind training, “because it's deeply, deeply transformative”.Different psychedelic drugs work in different ways. Some can trigger negative experiences if taken irresponsibly. According to Naina, MDMA is one of the best for pro-sociality and connectedness, because it produces very little bad experiences.Psychedelic experiences can be so transformative that it can be difficult to know what to do with them. Some kind of scaffolding around their use is needed, says Naina.“Even so, many studies now show that psychedelics are beneficial therapeutically, even just in themselves, even if you don't have a particular practice around them.”As a practicing Buddhist, Naina Gupta doesn't hold a certain metaphysics. The middle way means that you accept that reality cannot be framed or pinned down. Something is, isn't, is both and is neither, at the same time.“It's just unbelievable potential.”The cause of our suffering is the subject-object duality.Naina has several meditation practices, and she has trained herself to dream lucidly.Is this – learning how to liberate oneself from duality with the help of psychedelics, meditation and other spiritual practices – conducive to achieving a more peaceful world?“If there is any hope, it lies in this.”“I wouldn't be talking to you today if this wasn't needed.”Naina's personal page at the University of ExeterNaina on Linkedin

“They say it takes a village to raise a child. I really think it takes a village to treat a patient,” says Dr. Lanae Mullane, a naturopathic doctor and clinical strategist who has spent years at the forefront of bridging functional medicine, nutraceutical development, and digital health. In this episode of Raise the Line, host Lindsey Smith explores Dr. Mullane's view that naturopathic medicine complements conventional care by expanding -- not replacing -- the clinical toolkit, and that collaboration should be the future of medicine. “At the end of the day, collaboration and connection create the best outcomes for the people we serve,” she says. Their in-depth conversation also spans the shifting landscape of women's hormone health, including the perimenopausal transition and long-overdue calls for research equity. “We're not just smaller versions of men. We need to have dedicated research for us.” Tune in to learn about the importance of grounding health in sustainable habits, rethinking midlife care for women, and how to help patients take ownership of their health.Mentioned in this episode:Joi + BlokesSuppCoDr. Mullane's Clinical Website If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

In this episode of the Atomic Anesthesia Podcast, we tackle the complex reality of caring for patients under the influence of drugs or alcohol, a frequent challenge for nurse anesthesia residents and CRNAs. Covering the physiological effects and anesthetic implications of acute and chronic intoxication with alcohol, benzodiazepines, hallucinogens (such as LSD, PCP, and MDMA), cocaine, and cannabinoids, this episode offers fast, practical guidance for optimizing perioperative care and minimizing patient risk. Listeners will learn how substance use alters anesthetic requirements, impacts drug metabolism, and poses unique airway and hemodynamic risks, while also receiving actionable tips for drug class-specific management like when to use or avoid certain agents, the importance of invasive monitoring, and strategies for handling withdrawal or overdose. Tune in for a high-yield rundown that will help you make safer decisions when handling intoxicated patients in the OR.Want to learn more? Create a FREE account at www.atomicanesthesia.com⚛️ CONNECT:

בפרק זה מארח גיא קצוביץ' את עומר זרחיה, שקיבל רישיון ממשרד הבריאות להקמת מתקן לגידול וייצור של פטריות פסילוסיבין (פטריות פסיכדליות). בפרק מטלטל הוא מסביר כיצד הפטריות ו-MDMA מסייעות במצבים של דיכאון, פוסט טראומה ו-OCD, ולמה חומרים אלו הוצאו מהחוק למרות יעילותם שהוכחה בניסויים קליניים ובבתי חולים. (00:00) - פתיחה(03:07) - קנאביס רפואי בישראל(09:06) - ההיסטוריה של הפסיכדליה: למה יצא להם שם רע?(14:51) - חומרים פסיכדליים בישראל(25:05) - טיפול בפוסט טראומה(39:06) - כך נראה טיפול עם פטריות(48:44) - הסיכונים והסיכויים בטיפול פסיכדלי

Katie Treble grew up crying at about how all the king's horses and men couldn't put Humpty Dumpty together again. It was that compassion that made her the perfect candidate for doctoring during war as an adult.When Dr Katie Treble decided to swap the good vibes and beautiful beaches of Byron Bay for work with Médecins Sans Frontières (MSF) she knew she would be in for a shock. Nothing could have prepared her for the desperate need she encountered in the Central African Republic (CAR) in the midst of a civil war.But Katie was even more affected by the courage and kindness of her colleagues.She came away from her months in Bria, CAR knowing that her time as a humanitarian doctor would change her own life in deep ways, and so when she got back to Australia she started the work of trying to make sense of it all.Field Notes from Death's Door is published by HarperCollins.This episode of Conversations was produced by Meggie Morris, executive producer is Nicola Harrison.It explores medicine, university, war, civil war, Africa, humanitarian crisis, Gaza, Israel, Palestine, MSF, doctors without borders, access to medicine, hospital, conflict zones, PTSD, malaria, defence, navy, Kenya, France, Jamaica, Haiti, natural disaster, murder, infant mortality rate, vaccination, religious war, Islam, Christianity, genocide, MDMA therapy, psychology, recovery, healing.To binge even more great episodes of the Conversations podcast with Richard Fidler and Sarah Kanowski go the ABC listen app (Australia) or wherever you get your podcasts. There you'll find hundreds of the best thought-provoking interviews with authors, writers, artists, politicians, psychologists, musicians, and celebrities.

Wil Fisher is a San Diego based spiritual life coach and retreat leader dedicated to helping folks live lives of authenticity, freedom and joy! Before moving to San Diego, Wil spent many years in NYC where he earned his MA in Applied Theater, performed a solo show he wrote and produced, raised money for nonprofits, co-founded a company called Man Question, and created his drag alter ego, Sylvia London. After NYC, he served as executive director of Easton Mountain, a personal and spiritual growth retreat center for LGBTQ folks. Today, in addition to hosting his podcast, Queerly Beloved, and growing his coaching business, "Willfully Living," he also teaches improv to young adults on the autism spectrum. He's also writing a book exploring using the energy and wisdom of playfulness on one's spiritual journey. Episode Highlights▶ The Radical Fairy Movement and its influence on queer spirituality▶ Wil Fisher's journey from theater and nonprofit work to spiritual coaching▶ How earth-based practices helped him reconnect with spirituality▶ The role of self-love and authenticity in personal growth▶ Integrating spiritual principles into everyday life and coaching▶ Breaking free from societal and parental programming to find your true self▶ Healing through unconventional methods, from conscious kink to MDMA-assisted therapy▶ The importance of boundaries and safety in transformative work▶ How play and joy can be powerful tools for healing and connection▶ The future of healing rooted in creativity, self-expression, and communityWil Fisher's Links & Resources▶ Website: www.wil-fullyliving.com▶ Instagram:  https://www.instagram.com/wilfish99/▶ TikTok:  https://www.tiktok.com/@queerspirit▶ YouTube: https://youtube.com/playlist?list=PLH8Pj5n3XGM-7-lBnF5OtiYf3tlZERzlL&si=rk_cvNujMslJxtZf▶ Facebook: https://www.facebook.com/profile.php?id=100090026142775 Download Beth's free trainings here: Clarity to Clients: Start & Grow a Transformational Coaching, Healing, Spiritual, or Psychedelic Business: https://bethaweinstein.com/grow-your-spiritual-businessIntegrating Psychedelics & Sacred Medicines Into Business: https://bethaweinstein.com/psychedelics-in-business▶ Beth's Coaching & Guidance: https://bethaweinstein.com/coaching ▶ Beth's Offerings & Courses: https://bethaweinstein.com/services▶ Instagram: @bethaweinstein ▶ FB: / bethw.nyc + bethweinsteinbiz ▶ Join the free Psychedelics & Purpose Community: / psychedelicsandsacredmedicines

Harmony and Russell talk with researcher and author Matt Zemon about psychedelics as catalysts for change, not cures. They explore what current studies suggest about anxiety, PTSD, repetitive thinking, and addiction, then ground the conversation in practical guidance: source, set, and setting, medical intake, and the role of preparation and integration. The trio also contrasts medical and ceremonial lanes, the spiritual significance of entheogens, and how community transforms the healing arc—especially for veterans and for people navigating midlife transitions. What You'll Learn Catalyst vs. cure: why altered states create openness for change, and why integration is the practice that makes it stick Repetitive thinking patterns: how psychedelics may interrupt ruts that manifest as anxiety, depression, OCD, compulsions, or workaholism Source, set, and setting: a clear safety-first framework echoed by research institutions Preparation: clarifying intentions, tending physical space, and naming post-ceremony supports Integration: bringing insights into dishes, deadlines, and relationships, plus finding community that fits your path Medicine personalities: distinctions between ketamine, MDMA and MDA, psilocybin, LSD, ayahuasca, iboga/ibogaine, wachuma and peyote Risk basics: why independent medical consults matter, medications that conflict, and when supervised care is non-negotiable Spiritual context: clinical findings alongside living spiritual traditions, and why collaboration between science and spirit is needed now The information provided in this episode is for educational and informational purposes only. It does not constitute medical, psychological, or legal advice, and should not be relied upon as such. Psychedelic substances remain illegal in many jurisdictions, and their use carries physical, psychological, and legal risks.  If you are struggling with your mental health or substance use, please seek support from a licensed professional or contact your local mental health helpline. About Our Guest — Matt Zemon Matt holds a Master's in Psychology and Neuroscience from King's College London and is completing a Doctorate of Ministry at the Pacific School of Religion. He's the author of Psychedelics for Everyone, Beyond the Trip, and The Veteran's Guide to Psychedelics created with the Heroic Hearts Project. Matt works at the intersection of spirituality and mental health, helping communities and providers reduce risk and support meaningful, safe experiences. Resources Mentioned (pulled from the convo) Guest site: mattzemon.com Books: Psychedelics for Everyone, Beyond the Trip, The Veteran's Guide to Psychedelics Organizations and references mentioned: King's College London Pacific School of Religion Heroic Hearts Project Johns Hopkins, NYU, UCSF psychedelic research programs spiritpharmacist.com (Dr. Ben Malcolm), Dr. Emily Kopa On safety frameworks: source, set, and setting On community and faith-based contexts: Christian, Jewish, and Islamic psychedelic groups were referenced generally Call to Action Join Harmony's 21-Day Money Magic and Manifestation Challenge starting November 3 with a bonus live activation on Sunday, November 2. Check the show notes link to register, get the Manifestation Activation right away, and meet the community. Subscribe, rate, and review the show. Turn on automatic downloads. Say hello on Instagram: @findingharmonypodcast and @harmonyslaterofficial. Upcoming events: https://harmonyslater.com/events 21 Day Money Magic Manifestation Challenge: https://community-harmonyslater.com/landing/plans/1542444Use PROMO CODE for additional $20 Savings: MANIFESTATIONMAGIC  FREE Manifestation Activation: https://harmonyslater.kit.com/manifestation-activation FIND Harmony: https://harmonyslater.com/ JOIN the Finding Harmony Community: https://community-harmonyslater.com/ Harmony on IG: https://www.instagram.com/harmonyslaterofficial/ Finding Harmony Podcast on IG: https://www.instagram.com/findingharmonypodcast/ FREE 2 min breathwork practice: https://harmonyslater.com/morning-breathwork-optin Find your Spiritual Entrepreneur Archetype! Take the Quiz! https://harmonyslater.com/spiritual-entrepreneur-archetype-quiz BOOK Your Spinal Energetics Session: https://harmonyslater.as.me/

“It's kind of a miracle, frankly,” says Dr. John Buse, a distinguished professor at the University of North Carolina School of Medicine, referring to the effectiveness of GLP-1 receptor agonist medications such as Ozempic in treating type 2 diabetes, promoting significant weight loss, and reducing cardiovascular risk. As a physician scientist for the last three decades at UNC, Dr. Buse has played a key role in ushering in this new era of diabetes care, leading or participating in over 200 clinical studies on this class of drugs and others. “Nothing has impacted diabetes care like the GLP-1 receptor agonists. I have lots of patients whose diabetes was never well controlled who have seen all their metabolic problems essentially resolved.”  In this fascinating conversation with Raise the Line host Lindsey Smith, Dr. Buse not only explains how these drugs work, but also provides a clear-eyed look at side effects, and addresses issues of cost and access. Join us for the remarkable story – including the role played by Gila monsters -- behind one of the biggest developments in medicine over the past several years from a world renowned diabetes researcher and clinician. Mentioned in this episode:UNC School of Medicine If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

In this episode, we explore inner healing through altered states of consciousness. Joining me is Irina Vlada, a psychologist, author, and entrepreneur known for her pioneering work in developing holistic ketamine treatment programs that have led to profound personal transformations. Irina specializes in Psychedelics & Addiction Recovery, merging yogic tools for deeply life-transformative experiences. In the pod we talk about:·      Irina's personal journey from the Himalayan yogic tradition to psychedelics and ketamine.·      How psychedelics, spirituality, psychology, and wellness intersect for powerful inner healing. ·      How ayahuasca can facilitate profound psychological and spiritual experiences, while yoga provides the integrative framework for embodying change.·      How ketamine and yogic techniques like breathwork can synergize to create a more comprehensive healing experience. Please note! Ketamine is not a recreational drug. ·      We discuss the work of MAPS, the Multidisciplinary Association for Psychedelic Studies, researching the healing potential of MDMA and other psychedelics.The experiences expressed in this episode are purely personal and educational, and not intended for the promotion of ayahuasca, ketamine, or any other psychedelic modality.About Irina:Irina Vlada, PhD(c), Research in Psychedelics & Addiction Recovery | East West Psychology | Ketamine Integration | Awareness and Transformation Coach.She places a strong emphasis on the significance of psychedelic preparation and integration protocols to fortify the nervous system. Currently pursuing her PhD, Irina's research is centered around Neuroplasticity and Healing through altered states of consciousness. Irina's path is deeply rooted in the discovery and exploration of the authentic self. She is the co-founder of Evolve Wellness App, founder of Breathwise Coaching for personal transformation, and an Integration Coach with Mindbloom. References:https://www.instagram.com/irinavlada__/https://maps.orgThank you so much for listening, and thanks to my sponsors.This Episode is brought to you by: • The Sattva Collection - 10% off with code TheConsciousDiva• Birds & Beans Organic Coffee - 10% off with DIVA2025The Conscious Diva Podcast wouldn't be possible without your support! A massive THANK YOU for listening. If you'd like to further support my podcast, you can:• SUBSCRIBE in your favorite podcast player or YouTube.• FOLLOW me @The_Conscious_Diva on Instagram. • BOOK a session with Tatyanna.• SIGN-UP to receive emails at www.tatyannawright.com

החומר: כיצד משפיעים סוגים שונים של חומרים פסיכדלים, דוגמת פסילוסיבין ו-MDMA, על המוח האנושי? חוקר אורח: ד"ר ליאור רוזמן, חוקר פסיכדליה ומרצה בכיר באוניברסיטת אקסטר באנגליה.עורכת ומגישה: גיל מרקוביץ, עורכת: ויויאנה דייטש, תחקיר: ירין בר נוי, מפיקה: תמר בנימין, עיצוב קול: דימה קרנצובSee omnystudio.com/listener for privacy information.

Send us a textIn this episode of Small Cap Spotlight x WTR Healthcare Happenings podcast, WTR's Tim Gerdeman, and Robert Sassoon welcomes back Nick Kadysh, Founding CEO and President of PharmAla Biotech (OTCQB: MDXXF). The discussion explores the evolving global regulatory environment for psychedelics—particularly MDMA—the ripple effects of the Lykos Therapeutics FDA Complete Response Letter (CRL) disclosures, and PharmAla's strategic approach to research, manufacturing, and commercialization of clinical-grade MDMA and next-generation analogues.

“It wasn't a profession, it was a way of life,” observes internationally respected psychiatrist Dr. Nasser Loza, reflecting on a century-long family legacy in mental health care that began when his grandfather founded The Behman Hospital in Cairo. In this candid Raise the Line conversation with host Michael Carrese, Dr. Loza traces the transformation of psychiatry he's witnessed in his long career as increases in classifications, payment bureaucracy, reliance on pharmaceuticals, and technological disruption have each left their mark. The cumulative costs associated with these changes have, he laments, pushed care out of reach for many and hindered the human connection that is key to the discipline. He describes his prescription for countering these trends as a focus on effective and modest aims. “Rather than saying, come and see me in therapy for five years and I will make a better person out of you, I think focusing on symptom-targeted help is going to be what is needed.”  In this wide-ranging interview, you'll also learn about progress on advancing the rights of mental health patients and lowering stigmas, how to manage the rise of online therapy and use of AI chatbots, and the importance of empathy and transparency in mental health counseling. Don't miss this valuable perspective on a critically important dimension of healthcare that's informed by decades of experience as a clinician, government official and global advocate. Mentioned in this episode:The Behman HospitalMaadi Psychology Center If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

  In this episode, host Dr. Mike Hart welcomes neuroscientist and author Dr. Ben Rein to discuss his new book, 'Why Brains Need Friends: The Neuroscience of Social Connection.' Dr. Rein shares his journey in neuroscience, his research on autism and MDMA, and his pivot towards science communication. They delve into the devastating effects of loneliness, comparing its impact on mortality to smoking 15 cigarettes a day, and explore why human connections are critical for our brain health. Dr. Rein also discusses the benefits of having pets, the intricate balance of social interactions across a lifespan, the effects of MDMA on feelings of connection, and the role of oxytocin in social bonding. This episode provides a deep dive into the science behind social interactions, offering actionable insights to improve mental health and wellbeing.   Dr. Ben Rein is a neuroscientist, educator, and science communicator whose work explores the biology of human connection, empathy, and social behavior. With a Ph.D. in neuroscience and postdoctoral research at Stanford University, Dr. Rein has studied everything from the neural underpinnings of autism spectrum disorder to how MDMA (ecstasy) enhances empathy in the brain.   Follow his work at mindscience.org or connect with him on Instagram.   Links: Oxytocin (“the love hormone”) Loneliness and mortality studies Stanford University Lion's Mane   Show Notes: 00:00 Welcome back to the Hart2Heart podcast with Dr. Mike Hart 00:30 Dr. Ben Rein's background and new book 02:30 The loneliness epidemic and its effects 04:00 The science behind social interaction 04:15 “ Being isolated is worse for you or as bad for you as smoking 15 cigarettes a day.” 10:30 Extroversion vs. introversion: social needs 24:00 Oxytocin: the love hormone 33:00 Teamwork and social bonds 36:30 The power of tribalism in sports 38:00 Romantic relationships and health 42:00 The impact of loneliness across a lifetime 49:00 Social media and loneliness 01:02:00 The therapeutic potential of MDMA — The Hart2Heart podcast is hosted by family physician Dr. Michael Hart, who is dedicated to  cutting through the noise and uncovering the most effective strategies for optimizing health,  longevity, and peak performance. This podcast dives deep into evidence-based approaches to  hormone balance, peptides, sleep optimization, nutrition, psychedelics, supplements, exercise  protocols, leveraging sunlight light, and de-prescribing pharmaceuticals—using medications only when absolutely necessary.   Beyond health science, we tackle the intersection of public health and politics, exposing how  Policy decisions shape our health landscape and what actionable steps people can take to reclaim control over their well-being.   Guests range from out-of-the-box thinking physicians such as Dr. Casey Means (author of "Good Energy") and Dr. Roger Sehult (Medcram lectures) to public health experts such as Dr. Jay Bhattacharya (Director of the National Institutes of Health (NIH) and Dr. Marty Mckary  (Commissioner of the Food and Drug Administration (FDA) and high-profile names such as  Zuby and Mark Sisson (Primal Blueprint and Primal Kitchen).   If you're ready to take control of your health and performance, this is the podcast for you. We cut through the jargon and deliver practical, no-BS advice that you can implement in your daily life, empowering you to make positive changes for your well-being.   Connect on social with Dr. Mike Hart: Instagram: @drmikehart Twitter: @drmikehart Facebook: @drmikehart  

“When I was in medical school, no one had even heard of mitochondrial disease. Today, every student who graduates here knows what it is and has seen a patient with it,” says Dr. Mary Kay Koenig, director of the Center for the Treatment of Pediatric Neurodegenerative Disease at UTHealth Houston McGovern Medical School. That remarkable change in awareness has been accompanied by advances in genetic sequencing, the development of clinical guidelines, and the emergence of potential treatments in some forms of mitochondrial disease. In fact, Dr. Koenig's multidisciplinary team at UTHealth's Mitochondrial Center of Excellence has been a key player in clinical trials that may yield the first FDA-approved treatments for it. As you'll learn in this Year of the Zebra conversation with host Michael Carrese, her work in neurodegenerative diseases also includes tuberous sclerosis, where advanced therapies have replaced the need for repeated surgeries, and Leigh Syndrome, which has seen improvements in diagnoses and supportive therapies leading to better quality of life for patients.  Tune in as Dr. Koenig reflects on an era of progress in the space, the rewards of balancing research, teaching and patient care, and the need for more clinicians to center listening, humility and honesty in their approach to caring for rare disease patients and their  families.Mentioned in this episode:Mitochondrial Center of ExcellenceCenter for the Treatment of Pediatric Neurodegenerative Disease If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

In this solo episode, I share how learning to listen to my body became the most powerful form of self-trust. From discovering why men actually enjoy selfish women to revealing how an unexpected MDMA experience healed parts of my marriage, this episode is an intimate look at what it means to live, love, and lead on your own terms.✨ If you're craving deeper conversations, real connection, and conscious love Join UNION to meet potential matches at a dinner party in NYC + LAorSubscribe to Substack to stay in the loop about upcoming events, workshops, and retreats for conscious loveThis is the new era of love, self-led, embodied, and deeply connected

Are you enjoying this? Are you not? Tell us what to do more of, and what you'd like to hear less of. The Reykjavík Grapevine's Iceland Roundup brings you the top news with a healthy dash of local views. In this episode, Grapevine publisher Jón Trausti Sigurðarson is joined by Heimildin journalist Aðalsteinn Kjartansson, and Grapevine friend and contributor Sindri Eldon to roundup the stories making headlines in recent weeks. On the docket this week are: 00:00:55 Overview Of This Weeks Stories00:04:00 Strange Place Names In IcelandicWe discuss a random assortment of strange names of places in Iceland00:11:00 A Drunk Man Arrested For Taking A Nap On A Coast Guard ShipThe police arrested a man who had “taken up residence” in the the Icelandic coast guard ship Thor (Þór) this weekend. No further details were given about the incident.00:16:50 Iceland And Germany Sign A Defense AgreementOn Sunday, Þorgerður Katrín Gunnarsdóttir, Iceland's Minister for Foreign Affairs, and Boris Pistorius, Germany's Minister of Defense,  signed a bilateral declaration of intent on defense matters in connection with Pistorius' visit to Iceland. According to the declaration Iceland will build up infrastructure to accommodate military submarines and aircraft as a part of Iceland's membership in NATO. 00:21:40 Julian Assange Visits IcelandJulian Assange, the founder of Wikileaks, visited Iceland this weekend and was spotted at Vitabar, having a burger and fries. Assange, who was more or less in detention for 15 years was set free a year ago and now lives in Australia. 00:24:30 Drugs On A FerryThe only ferry to sale to Iceland on schedule, Norræna, which harbors in Seyðisfjörður, east Iceland, has been in the news recently for drugs. At the beginning of September, 7 kilos of cocaine were apprehended in a car on the ferry and two men arrested. Later in September, 15 kilos of Ketamine and 5 kilos of MDMA war found in another car on the ferry. Three people were arrested in the latter case.00:29:00 52% Think Church And State Should Be SeparatedA poll conducted recently tells us that 52% of Icelanders think that church and state should be separated. 27% are neither for nor against the motion, and 21% are opposed to separation. 00:39:40 Women's Strike 50th AnniversaryThis Friday, October 24th the famous 1975 Women's Strike turns 50. Tens of thousands are expected to celebrate this with a strike, and gather in downtown Reykjavík. ------------------------------------------------------------------------------------------SHOW SUPPORTSupport the Grapevine's reporting by becoming a member of our High Five Club: https://steadyhq.com/en/rvkgrapevine/You can also support the Grapevine by shopping in our online store: https://shop.grapevine.is------------------------------------------------------------------------------------------ This is a Reykjavík Grapevine podcast.The Reykjavík Grapevine is a free alternative magazine in English published 18 times per year, biweekly during the spring and summer, and monthly during the autumn and winter. The magazine covers everything Iceland-related, with a special focus culture, music, food and travel. The Reykjavík Grapevine's goal is to serve as a trustworthy and reliable source of information for those living in Iceland, visiting Iceland or interested in Iceland. Thanks to our dedicated readership and excellent distribution network, the Reykjavík Grapevine is Iceland's most read English-language publication. You may not agree with what we write or publish, but at least it's not sponsored content.www.grapevine.is

Maciej Lorenc, socjolog, członek zarządu Polskiego Towarzystwa Psychodelicznego tłumaczy na czym polegają cieszące się ostatnio dużym powodzeniem obrzędy zażywania silnych środków psychodelicznych. Nasz gość rozbiera na czynniki pierwsze rytuały Ayahuasca, San Pedro, Kambo i... jeszcze kilka innych. Ponadto po kolei wyjaśnia w jakich okolicznościach zostały wprowadzone do użycia wszystkie znane do tej pory substancje psychodeliczne: meskalina, psylocybina, LSD, DMT, MDMA, 5-MeO-DMT i ketamina. Z tej rozmowy dowiecie się również jakie zagrożenia wiążą się z zażywaniem psychodelików oraz czy można wykorzystać substancje psychoaktywne w leczeniu zaburzeń psychicznych - przede wszystkim depresji lekoopornej. Zachęcamy do słuchania, a także do zapoznania się z Najnowsza książką Maciej Lorenca "Czy psychodeliki uratują Polskę?".

Today, Kati sits down with neuroscientist Dr. Ben Rein, to dive into the social connection and the growing loneliness epidemic. Dr. Rein, author of Why Brains Need Friends, explains how your brain is fundamentally wired for interaction, why isolation is a biological stressor, and what you can do to improve your social health. In this must-watch episode, Dr. Rein explains the mechanical changes happening in your brain during isolation and clarifies why the U.S. Surgeon General has declared a loneliness epidemic. You'll learn the surprising truth about isolation and physical health—it can cause stress hormones like cortisol to rise within days and is associated with more adverse health outcomes. Dr. Rein also reveals the science behind why isolation can make people more irritable and even angry, linking it to the body's natural stress response. Kati and Dr. Rein discuss the difference between in-person and digital interactions, noting that less "lifelike" communication strips away vital social cues like eye contact, body language, and even smell, leading to fewer mood benefits. Dr. Rein introduces the concept of a "Social Diet" and social journaling—practical tools to help you identify which interactions energize you ("breath in" relationships) versus those that leave you depleted. The conversation takes fascinating turns into the role of brain chemicals like oxytocin and serotonin in social reward and the development of empathy. Plus, discover the incredible, innate ability of dogs to detect physiological stress signals and the science of how pets help children develop crucial social skills. By shopping with our sponsors, you help support our podcast: Green Chef https://www.greenchef.com/50ASKKATI HeadSpace https://www.headspace.com/ASKKATI Timestamps 00:00 - Introduction to Dr. Ben Rein, neuroscientist and author of Why Brains Need Friends. 02:54 - The neuroscience behind loneliness-induced anger and why isolation is treated as a stressor by the body. 05:57 - Debunking the myth: Do introverts benefit from social interaction, and in what dose? 10:48 - The evolutionary reason we are wired for social reward, and the key brain chemicals involved: dopamine, oxytocin, and serotonin. 15:40 - A discussion on MDMA, serotonin depletion, and the severity of the drug's comedown. 21:11 - The shocking statistics on increasing time spent alone in modern society (36 hours more per month). 28:22 - What is "inter brain synchrony," and can it happen over a text message?. 35:47 - The power of social smells: how tears can reduce aggression and how a mother's scent affects a baby's brain synchrony. 41:51 - Why growing up with dogs helps children develop empathy and fewer conduct problems. 48:53 - The powerful therapeutic properties of oxytocin (anti-inflammatory, neuroprotective) beyond just social connection. Ask Kati Anything ep. 284 | Your mental health podcast, with Kati Morton, LMFT Today's guest is Dr. Ben Rein https://www.youtube.com/@dr.benrein Order Ben's new book Why Brains Need Friends → https://geni.us/WhyBrainsNeedFriends My new book Why Do I Keep Doing This? is available for pre-order! https://geni.us/XoyLSQ If you've ever felt stuck, this book is for you. I'd be so grateful for your support. MY BOOKS Traumatized https://geni.us/Bfak0j Are u ok? https://geni.us/sva4iUY ONLINE THERAPY (enjoy 10% off your first month) While I do not currently offer online therapy, BetterHelp can connect you with a licensed, online therapist: https://betterhelp.com/kati PARTNERSHIPS Nick Freeman | nick@biglittlemedia.co Disclaimer: The information provided in this video is for educational and informational purposes only and is not intended as medical or mental health advice. It should not be used to diagnose or treat any health problem or disease. Always consult with a qualified healthcare professional for diagnosis and treatment. Viewing this content does not establish a therapist-client relationship. Learn more about your ad choices. Visit megaphone.fm/adchoices

Send us a textI was really intrigued when I heard about Matt Zemon and his advocacy for psychedelic therapy as an alternative when traditional psychotherapy hasn't been successful. Colorado became the first state in the country to legalize therapy using psilocybin mushrooms, and I know someone who has done it and says it produced great results. Like many of you, I came from a place of complete ignorance on this topic, so I really appreciate Matt's expert knowledge on it, and he enlightened me on information like about the hundreds of psychedelic churches and societies in this country. He has a very broad knowledge of using medicines like psilocybin, ketamine, ayahuasca, MDMA, and other psychedelics, why for some people these are better than antidepressants, who should consider taking one of these, like veterans dealing with post-traumatic stress, or people wanting to explore spiritual growth, the research that has gone into psychedelics, government views and laws on them, and places where people can consult with professionals if they want to explore trying these medicines. In particular, Matt supports veteran communities with his book, “The Veteran's Guide to Psychedelic Journeys” helping them find more healing and hope by combining ancient healing traditions with contemporary practices. He is donating all of the book's proceeds to the Heroic Hearts Project, which further aids veterans to heal. It's a fascinating conversation that I would encourage you to listen to because it may resonate for you or someone you know, and it will open your eyes in a lot of unexpected ways.Matt Zemonmattzemon.comFacebook and Instagram @matt.zemonLinkedIn linkedin.com/in/mattzemonBill Stahlsilly_billy@msn.comFacebook Bill Stahl and American Heroes Run for race photosInstagram and Threads @stahlor and @we_are_superman_podcastYouTube We Are Superman PodcastSubscribe to the We Are Superman Newsletter!https://mailchi.mp/dab62cfc01f8/newsletter-signupSubscribe to our Substack for my archive of articles of coaching tips developed from my more than three decades of experience, wild and funny stories from my long coaching career, the wit and wisdom of David, and highlights of some of the best WASP episodes from the past that I feel are worthwhile giving another listen.Search either We Are Superman Podcast or @billstahl8

“Giving learners options gives them a better learning experience. It's more holistic and more comprehensive,” says Sean Moloney, CEO and founder of EmbodyXR, an extended reality platform focused on the use of immersive technologies in medical education. In this eye-opening Raise the Line conversation, Moloney explains how AI-powered extended reality (XR) --which integrates augmented, virtual, and simulation-based environments -- allows learners to interact with patients, explore multiple diagnostic choices, and experience varied outcomes based on their decisions. The result, he notes, is not only stronger engagement in learning, but a measurable improvement in understanding. Despite these gains, Moloney is quick to point out that he sees these technologies as complements to traditional training, not substitutes for it. “We'll never replace in-person teaching,” he says, “but we can make learners even better.” Beyond training future clinicians, the EmbodyXR platform is also offering new modes of patient and caregiver education, such as augmented reality guidance for using medical devices at home. Join host Lindsey Smith as she explores how EmbodyXR achieves and maintains clinical accuracy, the connectivity it offers between headsets, personal computers and mobile devices, and other capabilities that are shaping the future of how healthcare professionals and patients will learn. Mentioned in this episode:EmbodyXR If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

111. Trip Report: Kanna vs. MDMA Plus How Molly Effs With Your Sleep For WeeksWhat if you could feel more connected, relaxed, and joyful—without alcohol or MDMA? In this episode, I talk to Andrew Weisse, founder of getKanna and writer of Substack's The Psychedelic Blog, about the mood-enhancing, heart-opening power of Kanna, a South African plant that's gaining popularity as a functional empathogen. We discuss its chemical makeup, traditional use, and modern applications for social connection, romantic intimacy, and MDMA replacement. This is a big one for anyone exploring a sustainable way to engage with psychedelics.

In this episode, you'll discover:Whether mystical states are just neurons firing or something science can't explain yetWhy human morality keeps evolving and what that means for the stories we call truthHow to use technology to train your focus without losing the magic of transcendenceHave you ever noticed how the though ts that torture you most aren't even yours?They're hand-me-downs. Scripts you inherited from parents who inherited them from their parents. Cultural programming that told you productivity equals worth. That rest is laziness. That your value comes from how much you can do for everyone else. You've been running on these thoughts for so long you forgot they're just thoughts. Not truth. Just noise.Most people think meditation is about becoming calm. It's not. It's about seeing the machinery. The way your brain spins the same stories on repeat. The way it reaches for distraction the second discomfort shows up. The way it convinces you that scrolling Instagram or buying another thing or staying busy will make you feel better when really you're just running from yourself.I spent years doing that. Chasing experiences. MDMA, plant medicine, skydiving. Anything to feel something other than the hollow ache of not knowing who I was underneath all the performance. Those experiences cracked me open. But they didn't teach me how to stay open. That's what meditation did. It taught me that the version of me chasing dopamine hits wasn't broken. She was just afraid to sit still long enough to meet herself.Today our guest is Ariel Garten, neuroscientist, psychotherapist, and founder of Muse, the brain-sensing meditation headband. She's lived with undiagnosed ADD her whole life and used meditation and neuroscience to literally rewire her brain.Links from the episode:Show Notes: mindlove.com/423Join the Mind Love CollectiveSign up for The Morning Mind Love for short daily notes to wake up inspiredSupport Mind Love SponsorsSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Why has America struggled so much to effectively manage the opioid use crisis? One of the answers, as you'll learn in this eye-opening episode of Raise the Line, is rooted in laws and attitudes from the early 20th century that removed addiction from the realm of medicine and defined it as a moral failing.  “The federal Harrison Act of 1914 forbade any physician from prescribing opioids to people with addiction, so it became more the purview of law enforcement or behavioral health or religion,” says Dr. Melody Glenn, who regularly confronts the consequences of this history during shifts in the emergency department at Banner-University Medical Center in Tucson, Arizona. And as Glenn explains to host Caleb Furnas, the resulting stigma associated with addiction has extended to the treatments for it as well, especially methadone, despite its effectiveness. Drawing on her dual expertise in emergency and addiction medicine, Glenn dispels misconceptions that medication-assisted treatment merely replaces one addiction with another, and emphasizes that harm reduction is critical to saving lives. Her desire to break prevailing stigmas led her to discover the story of Dr. Marie Nyswander, who pioneered methadone maintenance therapy in the 1960s and is featured in Dr. Glenn's new book, Mother of Methadone: A Doctor's Quest, a Forgotten History, and a Modern-Day Crisis. You'll leave this instructive interview understanding the roots of our flawed approach to addiction treatment, meeting an overlooked pioneer in the field, and admiring a devoted and compassionate physician who is following in her footsteps.  Mentioned in this episode:Banner-University Medical CenterMother of Methadone book If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Exploring Plant Medicine: Clinical Insights and Personal Transformation with Shawn Wells In this episode of the IRH Clinician's Corner, Margaret Floyd Barry welcomes back fan favorite Shawn Wells—an acclaimed nutritional biochemistry expert, supplement formulator, and author—for a fascinating conversation about the intersection of plant medicine and clinical practice. Margaret and Shawn dive into the rapidly evolving world of psychedelics, exploring both the science and profound personal transformations behind plant medicine. You will hear firsthand how these medicines can catalyze healing—emotionally, physically, and even relationally—providing fast-track breakthroughs for trauma, depression, and chronic stress.   In this interview, we discuss:       Shawn's personal journey with plant medicine and the changes that followed     How to approach and discuss the use of plant medicines in clinical practice     Types and levels of plant medicine and finding safe, competent facilitators      Preparing the body and mind for a plant medicine journey, as well as post-journey integration and support     How to support neuroplasticity and integration (through mindset and intention setting)     Microdosing: definitions and safe practices      Cautions and notes on practitioner responsibility The Clinician's Corner is brought to you by the Institute of Restorative Health. Follow us: https://www.instagram.com/instituteofrestorativehealth/   Connect with Shawn Wells: Website: https://shawnwells.com/ Instagram: https://www.instagram.com/shawnwells/ Facebook: https://www.facebook.com/Ingredientologist LinkedIn: https://www.linkedin.com/in/shawn-wells-supplements/ YouTube: https://www.youtube.com/c/shawnwells Author of ‘The ENERGY Formula' https://shawnwells.com/theenergyformula/   Timestamps: 00:00 "Sean Wells: Supplement Innovator" 10:08 "Mind-Blowing Psychedelic Experience" 13:20 "Discovering Self-Worth and Love" 21:41 "Psychic Healing and Clinical Support" 25:35 Ketamine: Clinical Use for Healing 31:16 "Master Clinical Skills, Transform Health" 33:40 "Choosing the Right Facilitator" 43:11 "Post-Event Recovery Timing Discussed" 50:30 "Flaws in SSRI Effectiveness" 55:46 "Echo Dosing for Integration" 57:20 Echo Dose and Sensory Remembrance 01:10:42 Conclusion Speaker bio:  Shawn Wells, MPH, LDN, RD, CISSN, FISSN is a globally recognized nutritional biochemistry expert with more than 20 years of experience in health, wellness, and product formulation. He has formulated over 1,100 products and holds 40+ patents, including enfinity® (Paraxanthine) and BHB salts. He has served as Chief Clinical Dietitian, Chief Science Officer, and advisor to multiple supplement companies, facilitating transactions exceeding half a billion dollars. Shawn authored the bestselling book The Energy Formula, featured by USA Today and Forbes, and he shares cutting-edge research on Mindvalley, in documentaries, and on his website shawnwells.com. He frequently speaks at events globally. Keywords:  Functional health, clinical skills, chronic disease, supplement formulation, nutritional biochemistry, plant medicine, psychedelics, trauma, practitioner support, microdosing, ayahuasca, psilocybin, MDMA, ketamine, neuroplasticity, nervous system regulation, intention setting, integration, generational trauma, default mode network, BHB salt, ketones, adaptogens, methylated B vitamins, hydration, Condor Approach, facilitator training, set and setting, dietary preparation, psychotherapy, neurogenesis Disclaimer: The views expressed in the IRH Clinician's Corner series are those of the individual speakers and interviewees, and do not necessarily reflect the views of the Institute of Restorative Health, LLC. The Institute of Restorative Health, LLC does not specifically endorse or approve of any of the information or opinions expressed in the IRH Clinician's Corner series. The information and opinions expressed in the IRH Clinician's Corner series are for educational purposes only and should not be construed as medical advice. If you have any medical concerns, please consult with a qualified healthcare professional. The Institute of Restorative Health, LLC is not liable for any damages or injuries that may result from the use of the information or opinions expressed in the IRH Clinician's Corner series. By viewing or listening to this information, you agree to hold the Institute of Restorative Health, LLC harmless from any and all claims, demands, and causes of action arising out of or in connection with your participation. Thank you for your understanding.  

Tohle je zkrácená verze (55min). Poslechni si celý díl (71min) s předplatným o týden dřív a bez reklam jen za stovku/měsíc.⁠ Odemkneš jich tím rovnou přes 50!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://podcasters.spotify.com/pod/show/brainweare/subscribe⁠⁠Dnes se Kryštof a Vojta baví o tom, jaké asi geny musí mít Charlie Sheen s ohledem na to, co zkonzumoval. Plynule přechází na drogový příběh Adolfa Hitlera a vojáků 2. Světové Války. Následně pak probírají vývoj vidění barev, vědomí a jeden z nejzajímavějších příběhů evoluce - molekula kofeinu. Je toho mnohem víc. Uslyšíte například:- Jaké budou lítosti naší generace při umírání?- Proč máme v kultuře nevyvážený shaming ohledně body-countu?- Jak se vypořádat s informačním zahlcením?KOREKCE: 16:21, tyčinky pro krátký vlnový délky jsou pro vnímání MODRÉ ne UV! Parťáci epizody:KusKakaa - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.kuskakaa.cz⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Přináší do Česka čistá ceremoniální kakaa. A proč si takové kakao dopřát? Ukazuje se, že přináší celou řadu benefitů a má velký obsah flavonoidů a polyfenolů. Tak jdi na ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.kuskakaa.cz⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ a zkus jedno z jejich kvalitních kakaí! Doporučujeme to z Kostariky, nebo Peru.Norsan.cz⁠ Norsan Vyrabí Omega 3 z čerstvého rybího oleje z udržitelného rybolovu nebo z mořských mikrořas. Jdi na Norsan.cz zadej kód bwa10 pro 10% slevu a pořiď si kvalitní OMEGA-3 tvůj mozek a zdraví ti poděkuje.⁠⁠⁠⁠⁠⁠⁠⁠⁠Uplife.cz⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ -Zadej kód "BWA" pro slevu 10% na vybrané zboží na eshopu ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.uplife.cz/brain-we-are/⁠⁠⁠⁠Kam dále?Kup si jeden z našich online kurzů ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Průvodce Mozkem a Myslí⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, nebo ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Mentální Modely⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ a s kódem "BWA30" je tam SLEVA 30%!Zadej kód "BWA" pro slevu 10% na vybrané zboží na eshopu ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠uplife.cz⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ a ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠herbal-store.cz⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Sledujte Brain We Are na sociálních sítích: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ( ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.instagram.com/brain_we_are⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ) nebo⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Facebook ⁠Minutáž:00:00 Úvod a dokument o Charliem Sheenovi06:18 Genetika, závislost a sebesabotáž08:02 Sláva, úspěch a vliv prostředí09:15 Hitler, d*ogy a doktor Morell17:56 Drogové experimenty a evoluce závislostí18:30 Čípky v oku a barevné vidění20:13 Emoce a vnímání červené barvy21:44 Evoluce kofeinu – rostliny a přežití23:40 Jak kofein vznikal nezávisle po světě25:40 Adenozin, únava a působení kofeinu27:27 Drogy u zvířat a evoluční význam psychoaktivních látek32:27 Stoned Ape hypotéza – drogy a vznik vědomí34:33 Vývoj jazyka, komunikace a kultura37:46 Chobotnice na MDMA a sociální chování38:53 Studie: omlazení opic pomocí kmenových buněk41:30 Etika využívání kmenových buněk a medicína budoucnosti43:27 Kmenové buňky, etika a vědecké hranice44:27 Body count - studie & Shaming na sociálních sítích51:44 Citát na poslední lítosti umírajících54:18 Přechod do VIP

Dr. K breaks down how psychedelics actually work not from hype or hearsay, but through neuroscience, psychiatry, and lived experience. He explains that psychedelics don't “heal” you by themselves; they temporarily put the brain into edit mode, a state of heightened neuroplasticity where your thoughts, emotions, and physiology can be rewritten for better or worse. Through a detailed look at serotonin receptors, brain connectivity, and decades of clinical research, Dr. K shows how substances like psilocybin, LSD, DMT, ayahuasca, and MDMA can rewire the brain and why they can just as easily cause harm if used without structure, safety, or integration. The episode also explores why guided psychedelic therapy — in a clinical or spiritual context — can lead to long-term healing, while unsupervised trips can lock trauma in even deeper. Dr. K ties it all together by connecting ego death to meditation and Vedic philosophy, revealing how both psychedelics and deep meditative practice dissolve the sense of self — and why that dissolution is often the real mechanism of healing. Topics include: The serotonin 2A receptor and why psychedelics increase neuroplasticity and neurogenesis How “edit mode” rewires your brain and how it can backfire Why integration therapy is critical after a psychedelic experience Set and setting: the real difference between healing and harm Which psychedelics work best for depression, PTSD, and addiction Why microdosing feels good but may not create long-term change The role of ego death and why it mirrors advanced meditation experiences Psychedelics vs. antidepressants - what the data actually says about efficacy and risk This episode is a deep dive into the science, safety, and spirituality of psychedelics offering clarity in a space often clouded by hype, myth, and misinformation. HG Coaching : https://bit.ly/46bIkdo Dr. K's Guide to Mental Health: https://bit.ly/44z3Szt HG Memberships : https://bit.ly/3TNoMVf Products & Services : https://bit.ly/44kz7x0 HealthyGamer.GG: https://bit.ly/3ZOopgQ Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of Diary of an Empath, I sit down with Dr. Ben Rein, a neuroscientist and science communicator, to explore the fascinating intersection between psychedelics and mental health.Dr. Rein breaks down what's actually happening in the brain when we use substances like psilocybin, MDMA, and ketamine—and how these compounds are being studied as potential treatments for depression, PTSD, and other mental health conditions.We dive deep into the science behind psychedelic therapy, the ethical considerations, and the importance of set and setting when it comes to healing safely and effectively. Dr. Rein also shares how social media has allowed him to make neuroscience more accessible to the public, bridging the gap between research and real-world understanding.This conversation challenges old stigmas, sheds light on groundbreaking research, and reminds us that healing isn't one-size-fits-all.In This Episode, We Discuss:What psychedelics do to the brain on a neurological levelThe latest research on psilocybin, MDMA, and ketamine in mental health treatmentThe potential benefits—and risks—of psychedelic therapyHow trauma and the nervous system interact with these substancesThe importance of intention, integration, and professional guidanceWhy education and accessibility are key to safe healingHow science communication on social media is changing the mental health landscapeDr. Ben Rein is a neuroscientist and science communicator whose work focuses on social behavior and mental health. He's known for translating complex research into digestible, relatable content on platforms like TikTok and Instagram, where he has built a massive community dedicated to understanding the brain and behavior.To get in Touch with Dr. Rein and to get a copy of his book:https://www.benrein.com/For psychic readings, Astrology, Therapy or Coaching with Keresse, click below:www.therapeutichealingbyreese.comFollow me on Instagram!https://instagram.com/_keresse_?utm_medium=copy_linkFollow me on Facebook!https://www.facebook.com/TherapeuticHealingByReese/TikTok:@DiaryofanEmpathpodcast

In this episode of Diary of an Empath, I sit down with Dr. Ben Rein, a neuroscientist and science communicator, to explore the fascinating intersection between psychedelics and mental health.Dr. Rein breaks down what's actually happening in the brain when we use substances like psilocybin, MDMA, and ketamine—and how these compounds are being studied as potential treatments for depression, PTSD, and other mental health conditions.We dive deep into the science behind psychedelic therapy, the ethical considerations, and the importance of set and setting when it comes to healing safely and effectively. Dr. Rein also shares how social media has allowed him to make neuroscience more accessible to the public, bridging the gap between research and real-world understanding.This conversation challenges old stigmas, sheds light on groundbreaking research, and reminds us that healing isn't one-size-fits-all.In This Episode, We Discuss:What psychedelics do to the brain on a neurological levelThe latest research on psilocybin, MDMA, and ketamine in mental health treatmentThe potential benefits—and risks—of psychedelic therapyHow trauma and the nervous system interact with these substancesThe importance of intention, integration, and professional guidanceWhy education and accessibility are key to safe healingHow science communication on social media is changing the mental health landscapeDr. Ben Rein is a neuroscientist and science communicator whose work focuses on social behavior and mental health. He's known for translating complex research into digestible, relatable content on platforms like TikTok and Instagram, where he has built a massive community dedicated to understanding the brain and behavior.To get in Touch with Dr. Rein and to get a copy of his book:https://www.benrein.com/For psychic readings, Astrology, Therapy or Coaching with Keresse, click below:www.therapeutichealingbyreese.comFollow me on Instagram!https://instagram.com/_keresse_?utm_medium=copy_linkFollow me on Facebook!https://www.facebook.com/TherapeuticHealingByReese/TikTok:@DiaryofanEmpathpodcast

Dr. Robin Carhart-Harris is a neuroscientist and professor of neurology and psychiatry at the University of California, San Francisco, where he leads the Psychedelics Division. He is internationally recognized for pioneering research on psychedelics, brain function, and mental health. His studies have revealed how substances like psilocybin and LSD can “reset” brain networks and offer therapeutic potential for conditions such as depression and anxiety. Dr. Carhart-Harris is a leading voice in the renaissance of psychedelic science, making groundbreaking neuroscience accessible to both scientific and public audiences.In our conversation we discuss:(00:00) Misunderstandings people have about psychedelics(02:27) Differentiating psychedelics from drugs like ketamine, MDMA(08:39) Why people group all drugs together(14:57) History of ancestral use of psychedelics(21:46) Visions or insights during dark retreat(23:17) Biohacks for psychedelic experiences without compounds(29:10) Natural vs synthetic psychedelics and effects(32:28) Albert Hoffman's discovery of LSD(37:45) Findings from legal LSD human studies(45:55) Comparing SSRIs and psychedelics for depression(46:27) Clarification on psilocybin as treatment(48:49) Qualitative vs quantitative measures in trials(51:34) No difference between SSRIs and psychedelics?(54:21) Hesitations about psychedelics despite effectiveness(54:56) Why clinicians hesitate to provide both options(58:04) Downsides of SSRIs versus psychedelics(1:03:46) Dependency risk of SSRIs vs psychedelics(1:07:49) Personality traits suited for SSRIs vs psychedelics(1:12:54) Microdosing versus single high psychedelic doses(1:14:48) Placebo or real effects of microdosing(1:18:57) Brian Johnson's blueprint and psychedelics(1:20:32) Psychedelics and potential longevity benefits(1:26:01) Key takeaway and misconception to forget(1:29:04) Where to follow for book updatesLearn more about Dr. Robin:https://en.wikipedia.org/wiki/Robin_Carhart-Harrishttps://profiles.ucsf.edu/robin.carhart-harris@CarhartharrislabWatch full episodes on: https://www.youtube.com/@seankimConnect on IG: https://instagram.com/heyseankim

Send us a textWhat happens when talk therapy isn't enough? When the pain runs so deep that even the best therapist can't reach it? Curt Kearney joins today to share his personal story of turning to psychedelics as a last resort and how that decision changed the entire trajectory of his life.This is a deeply grounded conversation about trauma, treatment-resistant depression, and the inner parts we exile to survive. Curt breaks down how Internal Family Systems (IFS) and psychedelic-assisted therapy can work together to bring those parts back into relationship, sometimes for the first time in decades. This is not a conversation about quick fixes. It's about safety, trust, and the power of showing up for the parts of ourselves we were taught to bury.This Episode Covers:Curt's first experience with LSD at 17 and how it altered his mental health journey.The difference between exiles and protectors in IFS.How psychedelics can amplify self-compassion and internal clarity.The importance of preparation and consent in psychedelic work.A powerful case study of MDMA-assisted therapy for PTSD.Why “bad trips” often come from neglected parts not feeling safe.The role of integration and ongoing relationship with inner parts.What happens when the monster inside turns out to be you.Connect with Curt:LinkedIn - https://www.linkedin.com/in/curt-kearney-39824643/Website - https://www.curtkearney.com/Until next time, here's to deeper connections and personal growth.Mad love!The podcast is now on YouTube! If you prefer to watch, head over to https://www.youtube.com/playlist?list=PLw3CabcJueib20U_L3WeaR-lNG_B3zYqu__________________________________________Don't forget to subscribe to the Badass Confidence Coach podcast on your favorite podcast platform!CONNECT WITH ANNA:Instagram https://www.instagram.com/askannamarcolin/TikTok https://www.tiktok.com/tag/askannamarcolinEmail hello@annamarcolin.comWebsite https://www.annamarcolin.com

“We don't view a person with chronic pain as someone who has a chronic illness and the effect of that is we can't follow patients continuously over prolonged periods of time,” says Dr. Jacob Hascalovici, a neurologist and pain specialist based in New York City.  In co-founding Bliss Health, Dr. Jacob, as he is known, has set out to create a continuous care model for chronic pain treatment that matches the approach taken for patients with diabetes or high blood pressure. The Bliss Health formula includes an initial meeting with a physician that produces a care plan; remote therapeutic monitoring on an ongoing basis; and a monthly meeting with a nurse to review data and determine next steps, including additional appointments with physicians as needed.  All of this occurs via a digital platform which provides a welcome option for patients with mobility issues and can fill gaps in access to specialists, especially in rural areas. Dr. Jacob is also hoping to make chronic pain patents feel respected, which is not always the case in their encounters with the healthcare system. “Because pain is not something that can be seen or measured, oftentimes patients feel marginalized, dismissed and disempowered by providers.” Join Raise the Line host Lindsey Smith for a valuable conversation that also touches on policy changes that could strengthen telemedicine, and has details on the first non-opioid based pain medication to receive FDA approval in over 20 years.Mentioned in this episode:Bliss Health If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

In another powerful episode of the Bare Knuckle Recovery Podcast, hosts Tommy Streeter and Nate Moellering welcome special guest Warren Gumpel, a leading voice and educator on ketamine and psychedelic-assisted therapy.Warren shares his deeply personal journey, including his struggle with depression, anxiety, and substance use issues which eventually led him to a life-saving discovery: ketamine treatment. Ten years ago, after a couple of treatments, his depression, anxiety, and suicidal thoughts were gone.Inside the ConversationThe Power of Neuroplasticity: Warren breaks down a critical concept: ketamine is not a "silver bullet". Instead, it acts as a powerful catalyst and provides a window of heightened neuroplasticity —the brain's ability to build new thought patterns and neurons —allowing a person to implement the necessary behavioral changes in their daily life.Dissociation and Trauma: The discussion dives into the dissociative aspect of ketamine, explaining how it temporarily shuts off the brain's "default mode network" (the inner ego and narrative). This process allows an individual to gain a critical distance from traumatic memories, enabling them to re-examine and recontextualize them without the overwhelming physiological "fight or flight" response; an effect that works synergistically with therapies like EMDR.Best Practices and Safety: The conversation covers the difference between outpatient and inpatient care with inpatient facilities like Allendale Treatment offering the optimal environment for building durable habits away from triggers. Warren stresses the importance of a multidisciplinary screening approach and cautions against recreational use, emphasizing that these medicines must be used as part of a therapeutic process with medical supervision.The Psychedelic Horizon: Warren gives an exciting look at the future of mental health treatment, touching on the efficacy of MDMA for PTSD (especially for veterans) and psilocybin for treatment-resistant depression.A Story of Redemption: Hear the incredible story behind the documentary "Lamar Odom Reborn", where Warren helped the NBA star through his own ketamine and Ibogaine treatments following a near-fatal overdose. This moving example showcases the incredible hope and transformation possible for those struggling with trauma and addiction.Don't miss this crucial conversation about innovation, hope, and the critical work being done to change the landscape of mental health and addiction recovery.Discover more episodes and watch the video version of this episode on YouTube or at www.bareknucklerecovery.comWatch this episode here: https://www.bareknucklerecovery.com/

This week, Vee and Elle sit down with journalist and sexual freedom philosopher Nicolle Double L to explore the intersection of BDSM, psychedelics, and sexuality as tools for self-discovery and healing. The conversation dives into cervical orgasms, DMT release, altered states, and how sex can mirror a psychedelic journey, especially when paired with presence and aftercare. The discussion delves into the neurochemistry of orgasms, the therapeutic aspects of BDSM, and the significance of set and setting in both sexual and psychedelic experiences.Chapters: Introduction and Connection To Writing, Shame, and BDSM (00:00)The Role of MDMA and Psychedlics in Healing (13:49)Does MDMA Ruin Sober Sex? (17:03) The Neuroscience of Edging, Orgasms and Psychedlelics (25:40)The Parallels of Set, Setting and Integration After Sex/BDSM Experiences As Seen in Psychedelic Experiences (29:03)What is Integration?  Ex: Aftercare or Honest Space For Feedback & Reflection (32:30)Safe Space vs Brave Space (35:16)Do Cervical Orgasms release DMT?  (39:55)Visions and Taste Changes During Orgasms (47:18)The Descent of Inanna: The First Dominatrix?  (53:46)Rape Fantasy or Consual Non-Consent (CNC) (57:07)BDSM: Flow States, The Default Network Mode (DNM), the Suspension of Selfhood, Good Dom Vs Bad Dom  (59:28)Listener Q/A: If You Are Experimenting With Psychedlics, What Should Take Into Consideration To Not Have A Bad Experience?  (01:10:18)Nicolle Double L articles referenced in this episode:Can MDMA Increase Women's Sexual Desire?Do Orgasms Cause the Release of DMT?BDSM is the temporary suspension from the burden of selfhoodSign up for her substack to get more!The Sexual Freedom Philosopher Substack Follow:Instagram nicolledoublelInstagram menwhotakebathsLearn More:Nicolle Double L's LinkTreeWhere to find us, and how you can support us:Instagram: @girlsgonedeeppod Merch: girlsgonedeep.com/shop Woo More Play Affiliate Link: Support us while you shop! WHOREible Life: Get 10% off your deck with code GONEDEEP at whoreiblelife.com Instagram: @wlthegameContact: girlsgonedeep@gmail.com © 2025 GGD Alchemy, LLC. All Rights Reserved.

Episode 25 with Marsha Rosenbaum, PhD, is a journey back through the psychedelic time machine. Marsha started her medicine journey back in the 1970s, both as an underground explorer of psychedelics and an above-ground researcher for the National Institute on Drug Abuse (NIDA). For nearly 20 years, she was the Principal Investigator on grants from NIDA to study women heroin addicts, cocaine, methadone maintenance treatment, and MDMA. She then moved to drug policy and education at the Drug Policy Alliance in San Francisco (where she is Director Emerita) where she founded the Safety First drug education project. Back when Marsha, got her start, the general view was that all drugs were bad, which then led to the creation of the war on drugs and all its devastating impacts. Marsha is one of the many voices that has helped our society to come to the new understanding that some drugs can actually be very beneficial and that the drug war did more damage than any drug ever did. Join us for a trip through the psychedelic decades as we explore the amazing contribution of Marsha Rosenbaum to the evolution of drug research, policy and education.   Learn More About Marsha Rosenbaum, PhD Drug Policy Alliance: drugpolicy.org Safety First Program: https://drugpolicy.org/resource/safety-first/ Before You Trip: beforeyoutrip.org Coalition for Psychedelic Safety and  Education: https://www.coalitionforpsychedelicsafety.org   Connect with Carla If you're inspired by this episode and want to stay connected, follow Carla and Psychedelic Divas on social media or visit the website to get your Psychedelic Safety Guide Including What to Do When Things Go Wrong: ·        Website: PsychedelicDivas.com ·        Carla's Coaching: CarlaDetchon.com ·        Instagram: @psychedelicdivas ·        YouTube: @carladetchon  ·        Subscribe & Review: If you enjoyed this episode, please subscribe, rate, and review Psychedelic Divas. Your support helps amplify these important conversations and grow our community.

Delanie Fischer chats with Dr. Dave Rabin, board-certified psychiatrist, translational neuroscientist, and inventor, to discuss the future of mental health and medicine. They discuss the efficacy of psychedelic-assisted therapy, technological therapeutics, ancient modalities, and ground-breaking discoveries about consciousness. * This episode is not a substitute for medical advice. Please consult your doctor to determine which therapeutic practices are appropriate for you. Plus: + The Root of Mental Illness, Epigenetics, Trauma, and Consciousness + Psychedelics & Medications: Psilocybin, Ketamine, MDMA, and SSRIs + Near-Death Experiences, Synchronicities, and Extrasensory Ability Self-Helpless on Patreon: https://www.patreon.com/selfhelpless Your Host, Delanie Fischer: https://www.delaniefischer.com EPISODES RELATED TO THIS TOPIC: Depression and Serotonin Syndrome with Dr. Tracey Marks: https://www.delaniefischer.com/selfhelplesspodcast/episode/36a8f408/depression-and-serotonin-syndrome-with-dr-tracey-marks Rethinking Intuition, Belief, and The Nature of Reality with Vincent Genna: https://www.delaniefischer.com/selfhelplesspodcast/episode/23db0212/rethinking-intuition-belief-and-the-nature-of-reality-with-vincent-genna 7 Reasons Why You May Have Insomnia (And How To Treat It) with Dr. Brian F. Licuanan: https://www.delaniefischer.com/selfhelplesspodcast/episode/215f937b/7-reasons-why-you-may-have-insomnia-and-how-to-treat-it-with-dr-brian-f-licuanan 20+ Years Thriving with Stage IV Cancer with Kris Carr: https://www.delaniefischer.com/selfhelplesspodcast/episode/22f2b084/20-years-thriving-with-stage-iv-cancer-with-kris-carr Learn more about your ad choices. Visit megaphone.fm/adchoices

After her father's sudden death, she carried a "calcified" grief for 15 years that traditional therapy couldn't touch—until one psychedelic cannabis journey changed everything. This week, we're joined by psychotherapist Angela, founder of Altered Healing, for a fascinating deep dive into the world of psychedelic therapy. Angela challenges the "Cheetos and cartoons" stereotype, making the case for cannabis as a powerful medicine for healing trauma when used with intention. We discuss her incredible personal story, the crucial difference between recreational and therapeutic use, and how cannabis compares to other medicines like ketamine, psilocybin, and MDMA.You can watch this entire episode over on YouTube!Follow Sickboy on Instagram, TikTok and Discord.

Dr. Hoffman continues his interview with Dr. Jacob Teitelbaum, Integrative Medicine physician, researcher, and best-selling author.

In this episode of the Intelligent Medicine podcast, host Dr. Ronald Hoffman discusses the increasing prevalence of depression and anxiety, particularly among young people, with guest Dr. Jacob Teitelbaum, Integrative Medicine physician, researcher, and best-selling author. They explore potential causes, including societal factors, diet, sleep patterns, and the fear-inducing media environment. Dr. Teitelbaum shares insights from his expertise in both conventional and integrative medicine, emphasizing the role of nutritional support, such as magnesium, B vitamins, and curcumin, as well as the importance of psychological strategies, biophysical techniques like shaking off trauma, and natural remedies. They also delve into the potential benefits of alternative therapies like CBD, ketamine, and psychedelics for mental health conditions. Listeners are encouraged to consider a comprehensive approach to managing these pervasive mental health issues.

After her father's sudden death, she carried a "calcified" grief for 15 years that traditional therapy couldn't touch—until one psychedelic cannabis journey changed everything. This week, we're joined by psychotherapist Angela, founder of Altered Healing, for a fascinating deep dive into the world of psychedelic therapy. Angela challenges the "Cheetos and cartoons" stereotype, making the case for cannabis as a powerful medicine for healing trauma when used with intention. We discuss her incredible personal story, the crucial difference between recreational and therapeutic use, and how cannabis compares to other medicines like ketamine, psilocybin, and MDMA.Find Angela's work and the organizations mentioned:Altered Healing: https://alteredhealing.com/Holos Integrative Health (Ketamine Therapy): https://holosintegrativehealth.com/Bluestem Psilocybin Pilot Program for Vets: Bluestem.co/vetsYou can watch this entire episode over on YouTube!Follow Sickboy on Instagram, TikTok and Discord.

In this candid, practice-focused conversation, Joe is joined by Norwegian psychologist and researcher Ivar Goksøyr to explore how therapists' own healing journeys can measurably improve client outcomes—and why MDMA-assisted experiences, used thoughtfully, may be a uniquely powerful catalyst for professional development. Ivar shares lessons from Norway's psychedelic research team (PTSD and the world's first MDMA-for-depression trial), his clinic Psykologvirke in Oslo, and his online course, “The Wounded Healer,” which uses authentic footage from his FDA-approved MAPS volunteer MDMA sessions to illuminate real clinical processes, countertransference, and the “inner healing intelligence” as a working metaphor rather than dogma. The discussion ranges from implementation realities (laws, ethics, and conservative regulatory cultures) to the pragmatic: how an MDMA experience helped Ivar resolve chronic anxiety reactions in the therapy chair, reduced burn-out, increased receptivity, and improved attunement—changes he believes many clinicians can cultivate when personal growth is prioritized alongside methods training. He outlines a developing collaboration with the University of Oslo on Empathogen-Assisted Therapies Development—not to “dose for certification,” but to support therapists' self-awareness and resilience in legally sanctioned research contexts. They also compare compounds: why MDMA may be easier to integrate into mainstream psychiatry than classic tryptamines (fewer projective processes, more biographical focus, smoother affect regulation), while acknowledging the immense promise—and higher demands—of psilocybin and other psychedelics. Throughout, they emphasize humility, guardrails, and the need to keep learning as the field scales (with frank reflections on ketamine's mixed rollout and avoiding idealization/devaluation cycles). Highlights Why therapist factors often outweigh modality—and how personal work translates into better outcomes. Using real session video (with Ivar as participant) to normalize vulnerability, illuminate process, and train pattern recognition. Regulatory and ethical nuances of self-experience in training; building consensus before policy change. Inner healing intelligence as a clinical metaphor aligned with Rogers, Rank, and psychodynamic concepts (unconscious therapeutic alliance). MDMA vs. classic psychedelics for implementation; sequencing with ketamine in public systems. Global classroom: 270+ clinicians from every continent; course structure centered on reflection, discussion, and live analysis.

In recent months, public health advocates in the United States have raised concerns about proposed changes to vaccine policy, cuts to food assistance programs, rollbacks of environmental protections and reductions in public health staffing. Chief among them has been Dr. Georges Benjamin who, as executive director of the American Public Health Association (APHA) since 2002, has led national efforts to create a healthier America. Raise the Line host Lindsey Smith recently sat down with Dr. Benjamin to understand more about the current state of public health and explore the path forward, and learned that a top priority for APHA is battling the misinformation that Dr. Benjamin believes is fueling support for many of these changes. “The challenge we have right now is that as a society, we've gone into our little corners and live in our own ecosystems. More people are getting their information from a single source and they're not validating that information to make sure that it's true.” Tune into this thoughtful and timely conversation to hear Dr. Benjamin's advice for curbing the spread of misinformation, how APHA is trying to help people understand the value of public health initiatives, and what the U.S. can learn from other countries about improving public health. Mentioned in this episode:American Public Health Association If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Guest: Omar Mosleh, Toronto Star reporter The RCMP says it has dismantled one of the largest dark web drug networks in Canadian history, a GTA-based group called RoadRunna that was allegedly shipping about 400 packages of drugs a week across Canada, including through Canada Post. Seven people from Toronto, Brampton and Mississauga are facing charges after officers seized 75 kilograms of cocaine, MDMA, heroin, meth, ketamine and more than 10,000 pills.  But the RoadRunna bust is part of a larger story of how the dark web continues to be a hub for traffickers, how criminals are switching to more sophisticated tools from Bitcoin to Monero and even to encrypted apps like Telegram, and how police are finding cracks in what was once seen as an anonymous online safe haven.Experts warn that while these takedowns are significant, dark web markets rarely stay offline for long. This episode was mixed by Paulo Marques

Welcome to the Psychedelic Conversations Podcast!In this episode of Psychedelic Conversations, we speak with Simon Hinkly, producer of the powerful new documentary Boarding on Insanity. We explore Simon's personal journey into psychedelic training, his early experiences with LSD, and how a return to psychedelics—through formal training and guided sessions—has shaped his work today. We also delve into his current approach to MDMA-assisted relationship support, delivered online in a deeply intentional and ethical way. The conversation then bridges into the themes of the documentary, which addresses the long-term trauma of boarding school experiences—particularly among political leaders—and how these unresolved wounds affect personal and societal dynamics. Simon shares the film's core message: how to recognize inherited trauma and begin the process of giving it back. This is a moving, eye-opening discussion on healing, connection, and the evolving landscape of psychedelic therapy.Boarding On Insanity website:https://www.boardingoninsanity.com/Simon's interview with Piers Cross:https://www.piers-cross.com/an-evolving-man-podcast-12-simon-hinkly-growing-elders-and-discovering-purpose-cultivating-wisdom-as-you-ageAbout Simon:Simon Hinkly has been involved in the film industry for many years working as a First Assistant Director on feature films and TV series such as The Long Good Friday and My Beautiful Laundrette. Later as a producer of short films. He has worked as a producer, director and assistant director on over 50 feature films, shorts and documentaries. Simon brings a great passion for telling stories that have a big impact on the world. As a producer Simon was twice winner of the Kodak Film Awards for Best Short Films: Letters of Service (2004) and A Neutral Corner (2006).Connect with Simon:https://uk.linkedin.com/in/simon-hinkly-b209a5bThank you so much for joining us! Psychedelic Conversations Podcast is designed to educate, inform, and expand awareness.For more information, please head over to https://www.psychedelicconversations.comPlease share with your friends or leave a review so that we can reach more people and feel free to join us in our private Facebook group to keep the conversation going. https://www.facebook.com/groups/psychedelicconversationsThis show is for information purposes only, and is not intended to provide mental health or medical advice.About Susan Guner:Susan Guner is a holistic psychotherapist with a mindfulness-based approach grounded in Transpersonal Psychology, focusing on trauma-informed, community-centric processes that offer a broader understanding of human potential and well-being.Connect with Susan:Website: https://www.psychedelicconversations.com/Facebook: http://www.facebook.com/susan.gunerLinkedIn: https://www.linkedin.com/in/susan-guner/Instagram: http://www.instagram.com/susangunerTwitter: http://www.twitter.com/susangunerBlog: https://susanguner.medium.com/Podcast: https://anchor.fm/susan-guner#PsychedelicConversations #SusanGuner #SimonHinkly #PsychedelicPodcast #Microdosing #PsychedelicScience #PlantMedicines #PsychedelicResearch #Entheogens

On Day 9 of Sean "Diddy" Combs' federal trial, former personal assistant George Kaplan delivered compelling testimony that shed light on the inner workings of Combs' operations. Kaplan recounted an incident aboard a private jet in 2015, where he witnessed Combs allegedly assaulting singer Cassie Ventura. According to Kaplan, he heard glass shattering and saw Combs standing over Ventura, who was on her back with her legs up, seemingly trying to create space. Ventura reportedly screamed, "Isn't anybody seeing this?" as the altercation unfolded. Kaplan also described another episode where he observed Ventura with bruises under her eye, after which Combs instructed him to purchase over-the-counter remedies to conceal the injuries .Beyond these incidents, Kaplan detailed his responsibilities, which extended beyond typical assistant duties. He testified about preparing hotel rooms for Combs' events, ensuring they were stocked with specific items and later cleaning them to protect Combs' public image. Kaplan also mentioned procuring drugs like MDMA for Combs and maintaining a "medicine bag" containing substances such as ketamine and Wellbutrin. Despite expressing admiration for Combs, Kaplan stated that he ultimately resigned in December 2015 due to discomfort with the physical behavior he witnessed .On Day 9 of Sean "Diddy" Combs' federal sex trafficking and racketeering trial, rapper Kid Cudi (Scott Mescudi) delivered a compelling testimony detailing a series of unsettling events he attributed to Combs' jealousy over Cudi's brief relationship with Casandra "Cassie" Ventura in 2011. Cudi recounted receiving a distressed call from Ventura, warning him that Combs had discovered their relationship and had obtained Cudi's home address. Subsequently, Cudi found his Los Angeles home broken into, with Christmas gifts unwrapped and his dog locked in a bathroom. He reported the incident to the police. Weeks later, in early 2012, Cudi's Porsche was destroyed by a Molotov cocktail in his driveway—a retaliatory act he suspected was orchestrated by Combs. Although Combs later denied involvement during a meeting at a Los Angeles hotel, Cudi testified that he believed the incidents were meant to intimidate him.Cudi's testimony aligns with previous allegations made by Ventura in her 2023 lawsuit, where she claimed Combs threatened violence against both her and Cudi upon learning of their relationship. During his testimony, Cudi described Combs' demeanor during their confrontation as reminiscent of a "Marvel supervillain," noting his calmness and the unsettling nature of the encounter. These accounts contribute to the prosecution's narrative of Combs' alleged pattern of coercive and violent behavior to maintain control over individuals in his personal and professional life. Combs has pleaded not guilty to all charges, including racketeering conspiracy and sex trafficking, and faces the possibility of life imprisonment if convicted.Mylah Morales testified about a 2010 incident at the Beverly Hills Hotel during the Grammy Awards weekend. She recounted waking up to the sounds of a heated argument between Combs and Cassie Ventura. After Combs stormed out of the room, Morales found Ventura with visible injuries, including a swollen lip, a black eye, and knots on her head. Concerned for Ventura's safety, Morales took her to her own home and consulted a doctor friend, who advised that Ventura should visit the emergency room. However, Ventura declined to seek medical attention or involve the police. Morales expressed fear for her own safety, stating she was afraid of Combs and feared for her lifeFrederic Zemmour, manager at the L'Ermitage Hotel in Beverly Hills, also testified on Day 9. He stated that Combs' customer profile had several notes to staff, including one that warned he "always spills candle wax on everything and uses excessive amounts of oil." These details were presented to illustrate Combs' behavior and its impact on hotel staff and property.to contact me:bobbycapucci@protonmail.comsource:May 22, 2025 - Day 9 of testimony in the Sean ‘Diddy' Combs trial | CNN

“Probably the most exciting thing I've seen in gene therapy over the last ten years is we now have a lot of tools for selective delivery, which will hopefully make treatments more safe and a lot more successful,” says Dr. Jessica Duis, a geneticist and pediatrician focused on the management of individuals with complex, rare disorders. Dr. Duis, who has worked on several gene therapies that are now approved or progressing through the accelerated approval pathway, is currently VP of Clinical Development at GondolaBio, a clinical-stage biopharmaceutical company focused on developing therapeutics for genetic diseases. As you'll learn in this Year of the Zebra episode with host Lindsey Smith, Dr. Duis is encouraged by other recent advances in genetic technology as well, and thinks momentum will grow as breakthrough treatments emerge. “I think we're hopefully going to continue to see companies that are working in rare disease be more successful and really drive how regulators think about making decisions in terms of bringing treatments to patients. I think we're at the tip of the iceberg in terms of the future of truly transformational therapies.”  This wide ranging conversation also explores Dr. Duis' team approach to patient care, her work on clinical endpoints, the importance of patient communities, and her book series, Rare Siblings Stories.Mentioned in this episode:GondolaBioRareDiseaseDocElsevier Healthcare Hub on Rare DiseasesRare Sibling Stories If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

A school principal abruptly quits his 20-year career, then spirals into suicidal depression, before finding a complete transformation after experimenting with psilocybin mushrooms, frog venom, and MDMA. Hope Lives Here is a production of Voyage Media. The series is produced by Nat Mundel and Dan Benamor. This episode was executive produced by Michael (which is not his real name), and story produced by Sophie Lee. Starring Jonathan Regier as Michael and Roshelle Simpson as Charlotte. Original music by Derlis Gonzalez. Edited, sound designed, and mixed by James Scully. If you're enjoying the show, please leave us a 5-star review on Apple Podcasts, or anywhere you're listening, and subscribe now for future episodes. Learn more about your ad choices. Visit megaphone.fm/adchoices

Episode summary Joe and Mary dive into how platform censorship and shifting algorithms have reshaped psychedelic media, why DoubleBlind moved to a “newsletter-first” model, and what that's revealed about true audience engagement. They reflect on the post-2024 MDMA decision headwinds, state-level policy moves (wins and losses), and how funding, politics, and culture continue to reconfigure the field. They also explore alternatives to alcohol, chronic pain research, reciprocity around iboga/ibogaine, and lessons from PS25 (MAPS' Psychedelic Science 2025). Highlights & themes From platforms to inboxes: Social and search suppression (IG/FB/Google) throttled harm-reduction journalism; DoubleBlind's pivot to email dramatically improved reach and engagement. Post-MDMA decision reality: Investment cooled; Mary frames it as painful but necessary growth—an ecosystem “airing out” rather than a catastrophic pop. Policy pulse: Mixed year—some state measures stalled (e.g., MA), others advanced (e.g., NM; ongoing Colorado process). Rescheduling cannabis may add complexity more than clarity. Censorship paradox: Suppressing education makes use less safe; independent outlets need community support to keep harm-reduction info visible. Chronic pain & long COVID: Emerging overlaps and training efforts (e.g., Psychedelics & Pain communities) point beyond a psychiatry-only frame. Alcohol alternatives: Low-dose or occasional psychedelic use can shift habits for some; Mary stresses individual context and support beyond any single substance. Reciprocity & iboga: Rising interest (including from right-leaning funders) must include Indigenous consultation and fair benefit-sharing; pace of capitalism vs. community care is an active tension. PS25 field notes: Smaller, more manageable vibe than 2023; fewer “gold-rush” expectations; in-person dialogue beats online flame wars. Notable mentions DoubleBlind: Newsletter-first publishing; nurturing new writers and reported stories. Psychedelics & Pain Association / Clusterbusters: Community-driven models informing care and research (cluster headache protocols history). Books & media: Body Autonomy (Synergetic Press anthology); Joanna Kempner's work on cluster headaches - Psychedelic Outlaws; Lucy Walker's forthcoming iboga film. Compounds to watch: LSD (under-studied relative to MDMA), 2C-B, 5-MeO-DMT (synthetic focus), and broader Shulgin-inspired families.   Mary Carreon: [00:00:00] Okay, I'm gonna send it to my dad because he wants to know. Here Joe Moore: we go. Yeah, send it over. So, hi everybody. We're live Joe here with Mary Anne, how you doing today? Mary Carreon: I'm great Joe. How are you? Joe Moore: Lovely. I actually never asked you how to pronounce your last name does say it right? Mary Carreon: Yes, you did. You said it perfectly Joe Moore: lovely. Joe Moore: Um, great. So it's been a bit, um, we are streaming on LinkedIn, YouTube, Twitch X and Kick, I guess. Yeah. Kick meta. Meta doesn't let me play anymore. Um, Mary Carreon: you're in forever. Timeout. I got it. I got it. Yeah. Joe Moore: Yeah. I think they found a post the other day from 2017. They didn't like, I'm like, oh cool. Like neat, you Mary Carreon: know, you know. Mary Carreon: Yeah. That happened to me recently, actually. Uh, I had a post taken down from 2018 about, uh, mushroom gummies and yeah, it was taken down and I have strikes on my account now. So Joe Moore: Do you get the thing where they ask you if you're okay? Mary Carreon: Yes, with, but like with my searches though, [00:01:00] like if I search something or, or someone's account that has, uh, like mushroom or psychedelic or LSD or something in it, they'll be like, mm-hmm are you okay? Mary Carreon: And then it recommends getting help. So Joe Moore: it's like, to be fair, I don't know if I'm okay, but Yeah, you're like, probably not. I don't really want your help. Meta. Yeah. Mary Carreon: You're like, I actually do need help, but not from you. Thanks. Yeah, Joe Moore: yeah, yeah. Mary Carreon: So not from the techno fascists. Joe Moore: Oh, good lord. Yeah. Uh, we'll go there. Joe Moore: I'm sure. Mary Carreon: I know. I just like really dove right there. Sorry. Yeah. All right, so let's, Joe Moore: um, before we go, let's give people like a bit of, you know, high kicks on, on who is Mary, where you working these days and what are you doing? Mary Carreon: Yeah, thank you. My name is Mary Carryon and I am forever and first and foremost a journalist. Mary Carreon: I have been covering, I say the plant legalization spaces for the past decade. It's, it's been nine and a half years. Uh, on January 3rd it will be [00:02:00] 10 years. And I got my start covering cannabis, uh, at OC Weekly. And from there went to High Times, and from there went to Mary Jane, worked for Snoop Dogg. And then, uh, I am now. Mary Carreon: Double blind. And I have become recently, as of this year, the editor in chief of Double Blind, and that's where I have been currently sinking my teeth into everything. So currently, you know, at this moment I'm an editor and I am basically also a curator. So, and, and somebody who is a, uh, I guess an observer of this space more than anything these days. Mary Carreon: Um, I'm not really reporting in the same way that I was. Um, but still I am helping many journalists tell stories and, uh, I feel kind of like a story midwife in many ways. Just like helping people produce stories and get the, get the quotes, get the angles that need to be discussed, get the sentences structures right, and, um, uh, helping [00:03:00] sometimes in a visionary kind of, uh, mindset. Mary Carreon: So yeah, that's what I'm doing these days. Joe Moore: Oh, there it is. Oh, there you are. Love that. And um, you know, it's important to have, um, editors who kind of really get it from a lot of different angles. I love that we have a lot of alignment on this kind of, and the drug war thing and kind of let's, uh, hopefully start developing systems that are for people. Joe Moore: Yeah, absolutely. If you wanna just say that. Yeah, absolutely. Mary Carreon: Yeah, absolutely. Joe Moore: So, um, yeah, I almost 10 years in January. That's great. We um, it's so crazy that it's been that long. I think we just turned nine and a half, so we're maybe just a few, a few months shorter than your I love it. Plant medicine reporting career. Joe Moore: That's great. I love it. Um, yeah, so I think. I think one of the first times we chatted, [00:04:00] um, I think you were doing a piece about two cb Do you, do you have any recollection of doing a piece on two cb? Mary Carreon: I do, yes. Yes. Wait, I also remember hitting you up during an Instagram live and I was like, are you guys taking any writers? Mary Carreon: And you guys were like writers, I mean, maybe depending on the writer. Joe Moore: And I was like, I was like, I dunno how that works. Mary Carreon: Like me. Yeah. Joe Moore: Yeah. It was fun. It was fun to work with people like yourself and like get pieces out there. And eventually we had an awesome editor for a bit and that was, that was really cool to be able to like support young startup writers who have a lot of opinions and a lot of things to point out. Joe Moore: There's so much happening. Um, there was so much fraud in like wave one. Of kind of the psychedelic investment hype. There's still some, but it's lesser. Um, and it's really a fascinating space still. Like changing lives, changing not just lives, right? Like our [00:05:00] perspective towards nearly everything, right? Joe Moore: Yeah. Mary Carreon: Yes, absolutely. Absolutely. I mean, it's interesting because the space has matured. It's evolved. It's different than it was even, what a, I mean, definitely nine years ago, but even five years ago, even four years ago, even last year, things are different. The landscape is different than it was a year ago. Mary Carreon: And I, it's, it's interesting to see the politics of things. It's interesting to see who has money these days given like how hard it is just to kind of survive in this space. And it's interesting just to. Bear witness to all of this going down because it really is a once in a lifetime thing. Nothing is gonna look the same as it does now, as it, uh, then it will like in a, in a year from now or anything. Mary Carreon: So it's really, yeah. It's interesting to take account of all of this Joe Moore: That's so real. Uh, maybe a little [00:06:00] too real, like it's serious because like with everything that's going on from, um, you know, governance, governments, ai Yes. Drug policy shifts. Drug tech shifts, yes. There's so much interesting movement. Um, yes. Joe Moore: You, you know, you, you kind of called it out and I think it's really actually worth discussing here since we're both here on the air together, like this idea that the psychedelic market, not idea, the lived experience of the psychedelic market having shifted substantially. And I, I, I think there's a lot of causes. Joe Moore: But I've never had the opportunity to really chat with you about this kind of like interesting downturn in money flowing into the space. Mm-hmm. Have you thought about it? Like what might the causes be? I'm sure you have. Mary Carreon: Yeah. Yeah, I have. Yeah. I've thought about it. I mean, it's hard. Well, I don't know. I am really not trying to point fingers and that's not what I'm [00:07:00] trying to do here. Mary Carreon: But I mean, I think a lot of people were really hopeful that the FDA decision last June, not last June, the previous June, a year ago, 2024, June was going to open the floodgates in terms of funding, in terms of, um. In terms of mostly funding, but also just greater opportunities for the space and, uh, greater legitimacy granted to the psychedelic medicine space. Mary Carreon: Mm. And for those who might not know what I'm talking about, I'm talking about the, uh, FDA decision to reject, uh, MDMA assisted therapy and, um, that whole, that whole thing that happened, I'm sure if it, you didn't even have to really understand what was going on in order to get wind of that wild situation. Mary Carreon: Um, so, so maybe, yeah. You probably know what I'm talking about, but I, I do think that that had a great impact on this space. Do I think it was detrimental to this space? [00:08:00] I don't think so. We are in a growth spurt, you know, like we are growing and growing pains happen when you are evolving and changing and learning and figuring out the way forward. Mary Carreon: So I think it was kind of a natural process for all of this and. If things had gone forward like while, yeah, there probably would be more money, there would be greater opportunity in this space for people wanting to get in and get jobs and make a living and have a life for themselves in this, in this world. Mary Carreon: I don't know if it was, I don't know if it would necessarily be for the betterment of the space in general for the long term. I think that we do have to go through challenges in order for the best case scenarios to play out in the future, even though that's difficult to say now because so many of us are struggling. Mary Carreon: So, but I, but I have hope and, and that statement is coming from a place of hope for the future of this space and this culture. Joe Moore: Yeah. It's, um, I'm with [00:09:00] you. Like we have to see boom bust cycles. We have to see growth and contraction just like natural ecosystems do. Mary Carreon: Absolutely, absolutely. It has to be that way. Mary Carreon: And if it's not that way, then ifs, if. It's, it like what forms in place of that is a big bubble or like a, a hot air balloon that's inevitably going to pop, which, like, we are kind of experiencing that. But I think that the, I think that the, um, the, the air letting out of the balloon right now is a much softer experience than it would be if everything was just like a green light all the way forward, if that makes sense. Mary Carreon: So, Joe Moore: right. And there's, there's so many factors. Like I'm, I'm thinking about, uh, metas censorship like we were talking about before. Yes. Other big tech censorship, right? Mm-hmm. SEO shifts. Mary Carreon: Oh. Um, yes, absolutely. Also, uh, there were some pretty major initiatives on the state level that did not pass also this past year that really would've also kind of [00:10:00] helped the landscape a little bit. Mary Carreon: Um. In terms of creating jobs, in terms of creating opportunities for funding, in terms of having more, uh, like the perception of safer money flow into the space and that, you know, those, those things didn't happen. For instance, the measure for in Massachusetts that didn't go through and just, you know, other things that didn't happen. Mary Carreon: However, there have been really good things too, in terms of, uh, legalization or various forms of legalization, and that's in New Mexico, so we can't, you know, forget that there, and we also can't forget just the movement happening in Colorado. So there are really great things happening and the, the movement is still moving forward. Mary Carreon: Everything is still going. It's just a little more difficult than maybe it could have been Joe Moore: right. Yeah. Amen. Amen. Yes. But also, we Mary Carreon: can't forget this censorship thing. The censorship thing is a horse shit. Sorry. I'm not sure if I'm allowed to cuss, but it is, [00:11:00] but it is Joe Moore: calling it out and it's important to say this stuff. Joe Moore: And you know, folks, if you want to support independent media, please consider supporting Doubleblind and psychedelics today. From a media perspective, absolutely. We wanna wanna put as much out as we can. Yes. The more supporters we have, the more we can help all of you understand what's happening and yes. Joe Moore: Getting you to stay safer. Mary Carreon: Yeah, absolutely. And that's the whole difficulty with the censorship is that psychedelics today, and Doubleblind for instance, but also Lucid News, also other, uh, other influencers, other creators in the space, they like. What all of us are doing is putting out information that is ultimately creating a safer user experience. Mary Carreon: And so with the censorship, we are not able to do so anymore, which creates actually a lot of danger. So. Yeah, it's, it's difficult. The censorship is difficult, and if you are somebody who posts about psychedelics, I know that you know this and I am preaching to the choir. Joe Moore: Yeah. So can you talk a [00:12:00] little bit about you all at Double Blind made a major shift in the last number of months towards, uh, kind of not necessarily putting everything out there and, and kind of like, um, actually I don't even know the language you use. Joe Moore: What's the, what's the language you use for the kind of model shift you took on? Mary Carreon: Yeah, I mean, it's great. It's been a wild shift. It's been a wild shift. Um, what we are currently doing is we went to a newsletter first model, which instead of just posting onto a website for everyone to see, and then, um, you know, hopefully getting SEO hits and also posting on their, then posting those stories onto Instagram and Facebook and Twitter, and hoping to get traffic through social media. Mary Carreon: Uh, we decided that that was no longer working for us because it wasn't, um, because the censorship is so bad on, on social media, like on Instagram, for instance, and Facebook and Twitter, well, less on Twitter, [00:13:00] but still, nonetheless on social media, the censorship is so bad. And also the censorship exists on Google. Mary Carreon: When you Google search how to take mushrooms, double blinds is not even on. You know, our guide is not on the first page. It's like, you know, way the heck, way the heck down there. Maybe page 2, 3, 4, 5. I don't know. But, um, the issue, the issue with that, or, or the reason why rather that it's that way is because Google is prioritizing, um, like rehabilitation centers for this information. Mary Carreon: And also they are prioritizing, uh, medical information. So, like WebMD for instance. And all of these organizations that Google is now prioritizing are u are, are, are, are organizations that see psychedelic use through the lens of addiction or through drug drug abuse. So [00:14:00] again, you know, I don't know, take it for how you want to, I'm not gonna say, I'm not gonna tell anybody like what is the right way to use their substances or whatever. Mary Carreon: However, it's really important to have the proper harm reduction resources and tools available. Uh, just readily available, not five pages down on a Google search. So anyways, all of that said double blind was our traffic was way down. And it was looking very bleak for a while. Just we were getting kicked off of Instagram. Mary Carreon: We weren't getting any traffic from social media onto our website, onto our stories. It was a, it was a vicious kind of cycle downward, and it wasn't really working. And there was a moment there where Doubleblind almost shut down as a result of these numbers because there's a, like you, a media company cannot sustain itself on really low page views as a result. Mary Carreon: So what we [00:15:00] decided to do was go to a newsletter first model, which relies on our email list. And basically we are sending out newsletters three days a week of new original content, mostly, uh, sometimes on Wednesdays we repost an SEO story or something like that. Um, to just to engage our audience and to work with our audience that way, and to like to actually engage our audience. Mary Carreon: I cannot emphasize that enough because on Instagram and on Facebook, we were only reaching like, I don't know, not that many people, like not that many people at all. And all of that really became obvious as soon as we started sending out to our email list. And as soon as we did that, it was wild. How many, how many views to the website and also how many just open like our open rate and our click through rate were showing how our audience was reacting to our content. Mary Carreon: In other words. [00:16:00] Social media was not a good, in, like, was not a good indicator of how our content was being received at all because people kind of weren't even receiving it. So going to the newsletter first model proved to be very beneficial for us and our numbers. And also just reaching our freaking audience, which we were barely doing, I guess, on social media, which is, which is wild, you know, for, for a, an account that has a lot of followers, I forget at this exact moment, but we have a ton, double blind, has a ton of followers on, on Instagram. Mary Carreon: We were, we, we get like 500 likes or, you know, maybe like. I don't know. If you're not looking at likes and you're looking at views, like sometimes we get like 16 K views, which, you know, seems good, but also compared to the amount of followers who follow us, it's like not really that great. And we're never reaching new, like a new audience. Mary Carreon: We're always reaching the same audience too, [00:17:00] which is interesting because even with our news, with our, with our email list, we are still reaching new people, which is, which says just how much more fluid that space is. Mm-hmm. And it's because it's, because censorship does not at least yet exist in our inboxes. Mary Carreon: And so therefore email is kind of like the underground, if you will, for this kind of content and this type of material journalism, et cetera. So, so yeah. So it, it, it has been a massive shift. It is required a lot of changes over at double blind. Everything has been very intense and crazy, but it has been absolutely worth it, and it's really exciting that we're still here. Mary Carreon: I'm so grateful that Double-Blind is still around, that we are still able to tell stories and that we are still able to work with writers and nurture writers and nurture the storytelling in this space because it needs to evolve just the same way that the industry and the [00:18:00] culture and everything else is evolving. Joe Moore: Yeah, I think, I think you're spot on like the, when I watch our Instagram account, like, um, I haven't seen the number change from 107 K for two years. Mary Carreon: Absolutely. Same. And, um, same. Joe Moore: Yeah. And you know, I think, I think there's certain kinds of content that could do fine. I think, uh, psychedelic attorney, Robert Rush put up a comment, um, in response to Jack Coline's account getting taken down, um, that had some good analysis, um. Joe Moore: Of the situation. Go ahead. You had No, Mary Carreon: no, I'm just like, you know, I can't, when, when journalists are getting kicked off of these, of these platforms for their stories, for their reported stories, that's like, that is a massive red flag. And that's all I have to say. I mean, we could go into more, more details on that, but that is a [00:19:00] huge red flag. Joe Moore: Mm-hmm. Yeah. Um, for sure. The, I, yeah. And like I'm sure he'll get it back. I'm sure that's not for good, but I think he did. Okay, great. Mary Carreon: I think he did. Yeah. Yeah, I think he did. Joe Moore: Yeah. So thank you. Shout out to Jack. Yeah, thanks Jack. Um, and I think, you know, there's, there's no one with that kind of energy out there. Joe Moore: Um, and I'm excited to see what happens over time with him. Yeah. How he'll unfold. Absolutely unfold. Oh yeah. It's like, um. Crushing the beat. Mary Carreon: Oh yeah, absolutely. Especially the political, the political beat. Like, there's no, there's few people who are really tackling that specific sector, which is like mm-hmm. Mary Carreon: So exciting for a journalist. Joe Moore: Yeah. Um, so model shifting, like we all have to like, adapt in new ways. Kyle and I are still trying to figure out what we're gonna do. Like maybe it is newsletter first. Like I, I realized that I hadn't been writing for [00:20:00] years, which is problematic, um, in that like, I have a lot of things to say. Mary Carreon: Totally. Joe Moore: And nobody got to hear it. Um, so I started a substack, which I had complicated feelings about honestly. 'cause it's just another. Rich person's platform that I'm, you know, helping them get Andreessen money or whatever. And, you know, so I'm gonna play lightly there, but I will post here and there. Um, I'm just trying to figure it all out, you know, like I've put up a couple articles like this GLP one and Mushrooms article. Mary Carreon: I saw that. I saw that. Really? And honestly, that's a really, like, it's so weird, but I don't, like, it's such a weird little thing that's happening in the space. I wonder, yeah, I wonder, I wonder how that is going to evolve. It's um, you know, a lot of people, I, I briefly kind of wrote about, um, psychedelics and the GLP, is that what it is? Mary Carreon: GLP one. Joe Moore: GLP one. Say Ozempic. Yeah, just, yeah, Ozempic. Yeah, exactly. Mary Carreon: Yeah, exactly. I wrote about [00:21:00] that briefly last year and there were a bunch of people like obviously horrified, which it is kind of horrifying, but also there's a bunch of people who believe that it is extremely cutting edge, which it also is. Mary Carreon: So it's really interesting, really fascinating. Joe Moore: Yeah. Um, I remember Bernie Sanders saying like, if this drug gets as much traction as it needs to, it will bankrupt Medicaid. I guess that's not really a problem anymore. Um, but, but, uh, but so like naming it real quick, like it changed the way we had to digest things, therefore, like mushrooms get digested differently and, um, some people don't respond in the expected ways. Joe Moore: And then there was some follow up, oh, we, in the regulated model, we just do lemon tech. And then I was like, is that legal in the regulated model? And I, I don't know the answer still. Mm-hmm. Like there was a couple things, you know, if users know to do it, you know, I don't, I don't totally understand the regulated model's so strange in Oregon, Colorado, that like, we really need a couple lawyers opinions. Joe Moore: Right. I think Mary Carreon: yes, of course Joe Moore: the lawyers just gave it a [00:22:00] thumbs up. They didn't even comment on the post, which is, laughs: thanks guys. Um, Joe Moore: but you know, laughs: yeah. You're like, thank you. Joe Moore: Thanks and diversity of opinions. So yeah, there's that. And like GLP ones are so interesting in that they're, one friend reached out and said she's using it in a microdose format for chronic neuroinflammation, which I had never heard of before. Joe Moore: Whoa. And um, I think, you know, articles like that, my intent was to just say, Hey, researchers yet another thing to look at. Like, there's no end to what we need to be looking at. Abso Mary Carreon: Oh, absolutely, absolutely. You know, reporting on this space actually taught me that there's so much just in general that isn't being researched, whether that's in this space, but also beyond and how, um, yeah, just how behind, actually, maybe not, maybe behind isn't the right word, but it kind of feels from my novice and from my novice place in the, in the world and [00:23:00] understanding research, it's. Mary Carreon: Hard for me to see it as anything, but being behind in the research that we all really need, that's really going to benefit humanity. But also, you know, I get that it's because of funding and politics and whatever, whatever, you know, we can go on for days on all of that. Joe Moore: What's the real reason? What's the real reason? Joe Moore: Well, drug war. Mary Carreon: Yeah. Well, yeah, definitely the drug war. Nixon. Yeah. Yes, yes, definitely the drug war. Yeah. I mean, and just the fact that even all of the drug research that happens is, again, through the lens of addiction and drug abuse, so Joe Moore: mm-hmm. Hard to right. Yeah. Um, like ni a is obviously really ridiculous and, and the way they approach this stuff, and Carl Hart illustrates that well, and, Mary Carreon: oh man, yes, he does. Joe Moore: Like, I think Fadiman's lab in Palo Alto got shut down, like 67, 66 or 67, and like that's, you know, that was one of the later ones, Mary Carreon: right? And, Joe Moore: and like, Mary Carreon: and here we are. Joe Moore: The amount of suffering that could have been alleviated if we [00:24:00] had not done this is. Incalculable. Um, yes. Yes. Yeah. Mary Carreon: I mean the, yeah, it's hard to say exactly how specifically it would be different, but it's difficult to also not think that the fentanyl crisis and the opioid addiction rate and situation that is currently like plaguing the, the world, but particularly the United States, it's hard to think that it wouldn't be, like, it wouldn't be a different scenario altogether. Joe Moore: Right, right. Absolutely. Um, and it's, um, it's interesting to speculate about, right? Like Yeah. Yes. Where would we be? And Mary Carreon: I know, I know, I know, I know it is speculation. Absolutely. But it's like hard, as I said, it's hard not to think that things would be different. Joe Moore: Right. Right. Um, I like, there's two kind of quotes, like, um, not, this one's not really a quote. Joe Moore: Like, we haven't really had a [00:25:00] blockbuster psychiatric med since Prozac, and I think that was in the eighties or early nineties, which is terrifying. And then, um, I think this guy's name is James Hillman. He is kinda like a Jungian, um, educator and I think the title of one of his books is, we're a hundred Years Into Psychotherapy and the World is Still a Mess. Joe Moore: And I think like those two things are like, okay, so two different very white people approaches didn't go very far. Yes. Um, yes and laughs: mm-hmm. Joe Moore: Thankfully, I think a lot of people are seeing that. Mm-hmm. Um, finally and kind of putting energy into different ways. Um, Mary Carreon: yeah. Absolutely. I think, yeah, I mean, we need to be exploring the other options at this point because what is currently happening isn't working on many fronts, but including in terms of mental health especially. Mary Carreon: So mm-hmm. We gotta get going. Right? We [00:26:00] gotta get moving. Geez. Joe Moore: Have you all, have you all seen much of the information around chronic pain treatments? Like I'm, I'm a founding board member with the Psychedelics and Pain Association, which has a really fun project. Oh, that's interesting. Mary Carreon: Um, I've seen some of the studies around that and it's endlessly fascinating for obvious, for obvious reasons. Mary Carreon: I, um, we have a writer who's been working for a long time on a story, uh, about the chronic pain that has since. Become an issue for this, for her, for the writer. Mm-hmm. Um, since she had COVID. Mm-hmm. Since, since she is just like, COVID was the onset basically of this chronic pain. And, um, there she attended a psychedelics in pain, chronic pain conference and, uh, that has pretty much like, changed her world. Mary Carreon: Um, well, in terms of just the information that's out there, not necessarily that she's painless, but it's just, you know, offering a, a brand new, a brand new road, a brand new path that is giving her, [00:27:00] um, relief on days when the pain is, uh, substantial. laughs: Yeah. Mary Carreon: So that's interesting. And a lot of people are experiencing that as well. Joe Moore: Mm-hmm. So there's, there's a really cool set of overlap between the COVID researchers, long COVID researchers and the chronic pain people. 'cause there is Yes. This new science of pain that's yes. Our group, PPA put out like a really robust kind of training, um, for clinicians and researchers and even patients to get more educated. Joe Moore: And we're, we're getting, um, kind of boostered by cluster busters and we're kind of leveraging a lot of what they've done. Mary Carreon: Wait, what is a cluster buster? Joe Moore: Oh gosh. Um, so they're a 5 0 1 C3. Okay. Started with Bob Wald. Okay. Bob Wald is a cluster headache survivor. Oh, oh, oh, Mary Carreon: okay. Got it. Got it. Yes. So they're Joe Moore: the charity that, um, has been really championing, um, cluster headache research because they found a protocol [00:28:00] with mushrooms. Joe Moore: Yes, yes, yes. To eliminate. Mm-hmm. Yeah. Um, this really great, I Mary Carreon: love that. Joe Moore: This really great book was written by a Rutgers, um, I think medical sociologist or anthropologist psychedelic. Love laughs: that. Joe Moore: Joanna Kempner. Cool. Um, and it kind of talks about the whole, um, cluster busters saga, and it was, it was pretty cool. Joe Moore: Nice. So they've been at it for about as long as maps. Um, oh wow. Maybe a little earlier. Maybe a little later. Mary Carreon: I love that. Cool. I mean, yeah, that's really great. That's really great. Joe Moore: So we're copying their playbook in a lot of ways and Cool. We about to be our own 5 0 1 C3 and, um, nice. And that should be really fun. Joe Moore: And, uh, the next conference is coming up at the end of next month if people wanna check that out. Psychedelic. Nice. Mary Carreon: Nice, nice, nice. Cool. Joe Moore: Yeah, so that, like, how I leaned into that was not only did I get a lot of help from chronic pain with psychedelics and going to Phish shows and whatever, um, you know, I, and overuse for sure helped me somehow. Joe Moore: [00:29:00] Um, God bless. Yeah. But I, I like it because it breaks us out of the psychiatry only frame for psychedelics. Mm. And starts to make space for other categories. Mm-hmm. Is one of the bigger reasons I like it. Mary Carreon: Mm-hmm. Mm-hmm. Yes. Yes. Which, like, we need to be, we need to, we, no one else is gonna do it for us. We like the people in the space who are finding new uses for these substances need to be creating those, those pathways and those new niches for people to then begin studying, et cetera, and exploring and yeah. Mary Carreon: Making, making a proper avenue for, Joe Moore: right, right. And, you know, um, I don't know that this is a Maha thing, so No, I'm going there, I guess, but like, how do we kind of face squarely America and the world's drinking problems? Not [00:30:00] knowing what we know now about alcohol, you know what I mean? And then like, what are the alternatives? Joe Moore: You know, some, some writers out there on substack are very firm that everybody needs to not do any substance. And like all psychedelics are super bad and drugs are evil, you know, famous sub stackers that I won't name. But you know, like what is the alternative? Like, I, like we have to have something beyond alcohol. Joe Moore: And I think you've found some cannabis helpful for that. Mary Carreon: Yeah, I, you know, it's, it's interesting because it's, there are, there's definitely an argument to be made for the power of these substances in helping, I don't wanna, I don't wanna say curb, but definitely reduce the symptoms of, uh, wanting to use or to drink or to consume a specific substance. Mary Carreon: There's obviously there is an argument to be made. There are, there is ano another camp of people who are kind [00:31:00] of in the, in the, in the, in the realm of using a drug to get off of a drug isn't how you do it. However, and, and I do, it depends on the individual. It depends on the individual and the, and how that person is engaging with their own addiction. Mary Carreon: I think for whether or not the substances work, like whether psychedelics work to help somebody kind of get off of alcohol or get off of cocaine or stop using opioids or, you know, et cetera. Mm-hmm. However, I think like, when the situation is so dire, we need to be trying everything. And if that means, like, if, like, you know, if you look at the studies for like smoking cessation or alcohol use, mushrooms do help, psilocybin does help with that. Mary Carreon: Mm-hmm. But, you know, there's, there's a lot of, there's a lot of things that also need to happen. There's a lot of things that also need to happen in order for those, uh, that relief to maintain and to stick and to, uh, really guide [00:32:00] somebody off of those substances. Mm-hmm. It's not just the substance itself. Joe Moore: Right. So I'm, I'm explicitly talking like recreational alternatives, right. Like how do I Yeah. On per minute, like, am Anitas becoming helpful? Yeah, yeah. Are helpful and Yeah. Yeah. I think like even, um, normal. What we might call like normal American alcohol use. Like Yeah. That's still like, quite carcinogenic and like, um, absolutely. Joe Moore: We're kind of trying to spend less as a country on cancer treatments, which I hope is true. Then how do we, how do we develop things that are, you know, not just abstinence only programs, which we know for sure aren't great. Mary Carreon: Yeah. They don't work. Yeah. I don't, it's, it's difficult. Mm-hmm. It's difficult to say. Mary Carreon: I mean mm-hmm. I don't know. Obviously I, I, well, maybe it's not obvious at all for people who don't know me, but, you know, I exist in a, I exist in, in a world where recreational use is like, it's like hard to define what recreational use is because if we are using this, if we are using mushrooms or LSD even, or MDMA, [00:33:00] you know, there are so many, there's a lot of the therapy that can happen through the use of these substances, even if we're not doing it, you know, with a blindfold on or whatever and yeah, I think like. Mary Carreon: There is a decent swap that can happen if you, if you are somebody who doesn't wanna be, you know, having like three beers a night, or if you are somebody who's like, you know, maybe not trying to have like a bottle of wine at a night or something like that, you know, because like Americans drink a lot and a lot of the way that we drink is, um, you know, like we don't see it as alcoholism. Mary Carreon: Even though it could be, it could be that's like a difficult Joe Moore: potentially subclinical, but right there. Mary Carreon: Um, yeah. Yeah. It's like, you know, it's, um, we don't see it as that because everybody, a lot of people, not everybody, but a lot of people drink like that, if that makes sense. If you know mm-hmm. If you, if you get what I'm, if you get what I'm saying. Mary Carreon: So, you know, I do think that there's a lot of benefit that, I don't [00:34:00] know, having, like a, having a mushroom, having a mushroom experience can really help. Or sometimes even like low dose, low doses of mushrooms can also really help with, like, with the. Desire to reach for a drink. Yeah, totally. And, and AMS as well. Mary Carreon: I know that that's also helping people a lot too. And again, outside of the clinical framework. Joe Moore: Yeah. I'm, a lot of people project on me that I'm just like constantly doing everything all the time and I'm, I'm the most sober I've been since high school. You know, like it's bonkers that like Yeah. Um, and you know, probably the healthiest event since high school too. Joe Moore: Yeah. But it's fa it's fascinating that like, you know, psychedelics kind of helped get here and even if it was like For sure something that didn't look like therapy. Yeah, Mary Carreon: yeah, yeah, yeah. Absolutely. Absolutely. Yeah. I, I think, I think most of us here in this space are getting projected on as to like, you know, being like what Normies would consider druggies or something, or that we are just like, you know, high all the time. Mary Carreon: Um, [00:35:00] I know that that is definitely something that I face regularly, like out in the world. Um, but, you know, I would also, I would also argue that. Uh, like mushrooms have completely altered my approach to health, my approach to mental health, and not even having to consume that, you know, that substance in order or that, you know, that fun fungi, in order for me to like tap into taking care of my mental health or approaching better, uh, food options, et cetera. Mary Carreon: It's kind of like what these, it's like how the mushrooms continue to help you even after you have taken them. Like the messages still keep coming through if you work with them in that capacity. Right. And yeah, and also same with, same with LSD too. LSD has also kind my experiences with that have also guided me towards a healthier path as well. Mary Carreon: I, I understand that maybe for some people it's not that way, but, um, for me that substance is a medicine as well, [00:36:00] or it can be. Joe Moore: Yeah. Um, so. What are, what are some things popping up these days about like US drug policy that's like getting exciting for you? Like, are you feeling feeling like a looming optimism about a, a major shift? Joe Moore: Are you kind of like cautiously optimistic with some of the weird kind of mandatory minimum stuff that's coming up or? Mary Carreon: Yeah. Yeah. I mean, I know that there was a huge, a, a pretty huge shift over at the DEA and I wish I remembered, I wish I remembered his name. The new guy who's now, I believe the head of the DEA, I don't know enough information about it to really feel a way. Mary Carreon: However, I don't think that he's necessarily going to be serving us as a community here, uh, in the psychedelic space. I, you know, I just don't think that that's something that we can ever depend on with the DEA. Uh, I also don't think that [00:37:00] the DEA is necessarily going to be. All that helpful to cannabis, like the cannabis space either. Mary Carreon: Um, I know that, that Trump keeps kind of discussing or, or dangling a carrot around the rescheduling of cannabis. Um, for, he's been, he's been, but he's doing it a lot more now. He's been talking about it more recently. Uh, he says like, in the next like couple weeks that he's going to have some kind of decision around that, allegedly. Mary Carreon: But we will see also, I'm not sure that it's going to necessarily help anybody if we reschedule two. Uh, what from schedule one to schedule th two, three, schedule three. Joe Moore: Either way it's like not that useful. Right. Exactly. Mary Carreon: Yeah. Yeah, exactly. It's, um, just going to probably cause a lot more red tape and a lot of confusion for the state rec markets. Mary Carreon: So it's like something that we, it's like only ridden with unintentional, unintentional consequences. Unintended consequences. Mm-hmm. Because no one knows how it's really going to [00:38:00] impact anything, um, if, if at all. But I don't know. It's hard, it's hard to imagine that there won't be any, uh, like more complex regulatory issues for business owners and also probably consumers as well. Joe Moore: Hmm. Yeah. This guy's name's Terry Cole. Mary Carreon: Oh, the new DEA guy. Joe Moore: Yeah. Um, I don't know much about him. Terry. Yeah. Terry, I would love to chat. Mary Carreon: Yeah. Terry, let's talk. I'm sure your people Joe Moore: are watching. Yeah. So like, just let him know. We wanna chat. Yeah. We'll come to DC and chat it out. Um, yeah. It's, um, but yeah, I, Carl Hart's solution to me makes like almost most of the sense in the world to just end the scheduling system Absolutely. Joe Moore: And start building some sort of infrastructure to keep people safe. That's clearly not what we have today. Mary Carreon: No. But building an infrastructure around the health and wellness and uh, safety of [00:39:00] people is the exact opposite system that we have currently right now. Because also the scheduling system has a lot to do with the incarceration in the United States and the criminal just, or the criminal system. Mary Carreon: So, so yeah, like we can't disentangle the two really. Joe Moore: It just started, um, I feel negligent on this. Uh, synergetic press put out a book like a year or two ago called Body Autonomy. Mm-hmm. Um, did that one come across your desk at all? Mm-hmm. No. I wish basically contributed. Oh, nice. A number of people. So it's both like, um. Joe Moore: Drug policy commentary and then like sex work commentary. Oh, nice. And it was like high level, like love that really, really incredible love that detailed science based conversations, which is not what we have around this. Like, that doesn't make me feel good. So you should go to jail kind of stuff. Or like, I'm gonna humiliate you for real though. Joe Moore: Ticket. Yeah, Mary Carreon: yeah, yeah, yeah, yeah. Oh God. Uh, when you think about it like that, it just really also shows [00:40:00] just the uh, um, the level at which religion has also kind of fundamentally infused itself into the scheduling system, but also our laws, you know, like what you just said, this like, shame-based, I'm going to embarrass you and make you into a criminal when you know actually you are a law for the most part, a law abiding citizen, with the exception of this one thing that you're doing for. Mary Carreon: A, your survival and or your, like, your feeling good, wanting to feel good addressing pain. Um, there's a large, uh, like noise coming out of the front yard of my house right now. Hold on. Just a, it doesn't sound too bad. It doesn't sound too bad. Okay. Okay, good. Not at all. Not at all. Okay. Yeah, I had Joe Moore: people working on my roof all day and somehow it worked out. Joe Moore: Oh, good. Um, yeah. Um, yeah, it's, it's fascinating and I, I've been coming around like, I, I identify as politically confused, [00:41:00] um, and I feel like it's the most honest way I can be. Um, Mary Carreon: I am also politically confused these days, impossible to align with any, uh, party or group currently in existence at this exact juncture in American history. Joe Moore: I can't find any that I want to throw my dice in with. Nah. This idea of like fucking way being. Like what is the most humane way to do government as a way it's been put to me recently. And that's interesting. So it comes down to like coercion, are we caring for people, things like that. And um, I don't think we're doing it in a super humane way right now. Mary Carreon: Um, we, yeah, I am pretty sure that even if there was, I mean, I think that even if we looked at the data, the data would support that we are not doing it in a humane way. Joe Moore: So Mary Carreon: unfortunately, and Joe Moore: you know, this whole tech thing, like the tech oligarch thing, you kind of dropped at the beginning and I think it's worth bringing that back because we're, we're on all [00:42:00] these tech platforms. Joe Moore: Like that's kind of like how we're transmitting it to people who are participating in these other platforms and like, you know, it's not all meta. I did turn on my personal Facebook, so everybody's watching it there. I hope. Um, see if that count gets, Mary Carreon: um, Joe Moore: but you know, this idea that a certain number of private corporations kind of control. Joe Moore: A huge portion of rhetoric. Um, and you know, I think we probably got Whiffs of this when Bezos bought Washington Post and then Yes. You know, Musk with X and like yes. You know, is this kind of a bunch of people who don't necessarily care about this topic and the way we do, and they're like in larger topics too about humane government and like, you know, moving things in good directions. Joe Moore: Um, I don't know, thoughts on that rift there as it relates to anything you, wherever you wanna go. Yeah. Mary Carreon: Yeah. I mean, I don't think that they are looking at, I don't think that they are looking [00:43:00] at it the way that we are. I don't think that they can see it from their vantage point. Um, I think that like, in the, in a similar way that so many CEOs who run businesses have no fucking clue about what's actually happening in their businesses and the actual workers and, and employees of their businesses can tell them in more detail. Mary Carreon: Far more detail about what's actually happening on the, on the floor of their own business. Uh, I think that it is something like that. However, that's not to say that, you know, these, these CEOs who employ people who build the A algorithm are obviously guided to create the limitations on us as people who speak about drugs, et cetera, and are creating a algorithm that ultimately is looking at things in a very blanket way in terms of, uh, like we're probably seen on the same level as like drug dealers, if that makes sense. Mary Carreon: Which is obviously a much, you know, there's, [00:44:00] it's a very different thing. Um, so, you know, there's like these CEOs are giving directions to their employees to ultimately create systems that harm. Information flow and inform and, and like the information health of, of platforms and of just people in general. Mary Carreon: So it's hard to say because there's nuance there, obviously, but I would bet you that someone like Elon Musk doesn't really have a full grasp as to the, the nuances and details of what's even happening within, on the ground floor of his businesses. Because that's like, not how CEOs in America run, run, and operate. Mary Carreon: They're stupid companies. So, so yeah. And I feel like that, like, that's across the board, like that's across the board. That's how I, that's probably how Zuck is operating with Meta and Facebook, et cetera. And yeah, just likewise and across, across the whole, [00:45:00] across the whole spectrum. Joe Moore: Mm-hmm. Yeah. And I think, um, a thing. Joe Moore: Then as the people like, we need to keep looking at how can we keep each other informed. And that's kind of circling back to drug journalism like we do and like, um, other, other sorts of journalism that doesn't really get the press it deserves. Right. And I've been getting far more content that I find more valuable off of tragically back on Zucks platform like IG is getting me so much interesting content from around the world that no major outlet's covering. Mary Carreon: That's so interesting. Like what? Like what would you say? Joe Moore: Oh, um, uh, certain, um, violent situations overseas. Oh, oh, got it. Yeah, yeah, yeah. And, um, you know, that America's paying for, so like, you know, I just don't love that I don't have a good, you know, journalistic source I can [00:46:00] point to, to say, hey, like right. Joe Moore: These writers with names, with addresses, like, and offices here. Yes. You know, they did the work and they're held, you know, they're ethical journalists, so yes. You can trust them. Right. You know what I mean? Yes, Mary Carreon: yes. Yeah, yeah, yeah. I mean, all of this makes everything so much harder for determining, like, the censorship specifically makes it so much harder for the people to determine like, what's real, what's not. Mary Carreon: Because, because of exactly what you just said. Mm-hmm. Like, you know, we are, we are basically what that means, like what is required of the people and people who are consuming information is becoming a smart consumer and being able to determine what's real, what's not. How can we trust this individual? Mary Carreon: How can we not, which isn't analysis process that all of us need to be sharpening every single day, especially with the advent of AI and, uh, how quickly this, this type of content is coming at all of us. Like, especially if you're on TikTok, which many of us are, you know, like information comes flying at you 3000 miles an hour, and it's sometimes [00:47:00] really difficult to determine what's real, what's not, because AI is. Mary Carreon: AI is not where it's going to be, and it still is in its nascent phase. However, it's still pretty fucking good and it's still very confusing on there. So, so again, like the media literacy of the people needs to be sharpened every single day. We cannot be on there, we cannot be on the internet existing. Mary Carreon: That everything that we are seeing is real. Whether that's about, you know, these, um, the violence overseas, uh, happening at the hands of the United States, whether that is, uh, even drug information like, you know, et cetera, all of all of it. Or just like news about something happening at Yellowstone National Park or something that is happening in the, uh, at like. Mary Carreon: Um, like potential riots also happening at protests in downtown la, et cetera. Like all, all of it, we need to be so careful. And I think what that also, like, one way that [00:48:00] we can adjust and begin to develop our media literacy skills is talking to people maybe who are there, reaching out to people who are saying that they were there and asking them questions, and also sussing that out. Mary Carreon: You know, obviously we can't do that for all situations, but definitely some of them. Joe Moore: Yeah, absolutely. Like, Joe Moore: um, a quick pivot. Mm-hmm. Were you at PS 25? Mary Carreon: Yes, I was. What did I think? Uh, you know, I, I was running around like crazy at this one. I felt like I didn't even have a second to breathe and I feel like I didn't even have a second to really see anybody. I was like, worry. I was jumping from one stage to the next. Mary Carreon: However, I would say, uh, one of, one of the things that I have said and how I felt about it was that I felt that this, this event was smaller than it was two years ago. And I preferred that I preferred the reduction in size just because it was, uh, less over, less overwhelming [00:49:00] in an, in an already very overwhelming event. Mary Carreon: Um, but I thought that from the panels that I did see that everyone did a really great job. I thought that maps, you know, it's impressive that maps can put on an event like that. Um, I also was very cognizant that the suits were there in full effect and, uh, you know, but that's not unusual. That's how it was last time as well. Mary Carreon: And, um, I felt that there was Mary Carreon: a, uh, like the, the, the level of excitement and the level of like opportunity and pro, like the prosperous. The like, prospect of prosperity coming down the pipeline like tomorrow, you know, kind of vibe was different than last time. Mm-hmm. Which that was very present at the one, two years ago, uh, which was the last PS psychedelic science. Mary Carreon: Yeah. Um, anyways. Yeah. But it was, you know, it was really nice to see everybody. [00:50:00] I feel like in-person events is a great way for everybody in the psychedelic space to be interacting with each other instead of like keyboard warrioring against each other, you know, uh, over the computer and over the internet. Mary Carreon: I think that, um, yeah, uh, being in person is better than being fighting each other over the internet, so, yeah. Joe Moore: Mm-hmm. People seem to be a little bit more civil in person. Mary Carreon: Exactly. Exactly. Mm-hmm. And I think that that is something that we all need to be considering more often, and also inviting people from across the aisle to your events and creating peace, because in person it's a little different than it is. Mary Carreon: When you have the opportunity to, uh, yeah, like keyboard attack someone over the internet, it's like, yeah. It's just so silly. So silly. We look like fools. Like we look like absolute idiots doing that. And you know what? I cannot sit here and say that I haven't looked like an idiot. So, you know, it's like I'm not, I'm not talking from like a high horse over here, but, but you know, it's like, it's [00:51:00] better when it's in person. Mary Carreon: I feel like there's like more civil engagements that we can all have. Joe Moore: It's practice, you know? Yeah. We're learning. Yeah. We are. We should be learning, including us, and yes, of course. Um, I, I play a subtler game these days and, uh, you know, I, I, I, it's better when we all look a lot better in my opinion, because yes, we can inform policy decisions, we can be the ones helping inform really important things about how these things should get implemented and absolutely right. Joe Moore: Like, Mary Carreon: absolutely. Yeah, it does. It does. Nobody, any service, especially these medicines, especially these sacraments, especially these plants, these molecules, et cetera, if we are all sitting here fighting each other and like calling each other names and trying to dunk on one another, when like in reality, we are also all kind of pushing for the same thing more or less. Joe Moore: Mm-hmm. So a thing that [00:52:00] I, it's a, it's kind of a, I, I had a great time at PS 25. I have no, no real complaints. I just wish I had more time. Yeah, same. Um, same. Yeah. Our booth was so busy. It was so fun. Just good. And it was like, good. I, I know. It was really good. I'm trying to say it out loud. I get to talk at the conference before Rick did. laughs: Oh, oh, Joe Moore: the morning show they put us on at like seven 30 in the morning or something crazy. Oh my god. It was early. I dunno if it was seven 30. Mary Carreon: That's so early. That's so early. Joe Moore: Yeah, right. Like that's crazy. I got zero nightlife in That's okay. Um, I was not, I was there for work. Yeah, Mary Carreon: yeah. I was Joe Moore: jealous. I didn't party, but you know, whatever. Joe Moore: Yeah, yeah. Mary Carreon: I did not party this time really in the same way that I did at PS 20. Was it 2023? Joe Moore: 23, yeah. 23. I only stay up till 11 one night in 23. Nice. Mary Carreon: Okay. Um, okay. Joe Moore: So I behaved, I have a pattern of behaving. 'cause I like That's good. I'm so bent outta shape inside going into these things. I'm like, I know, I know. Joe Moore: And, and I'm like, oh, all [00:53:00] my friends are gonna be there. It's gonna be great. And then it's like, yeah. It's mostly friends and only a little bit of stress. Yeah. Um, yeah. Yeah, Mary Carreon: yeah. I had a, I had a great time. It was really good seeing everybody again. Like you, I wish that I had more time with people. Like there are people that I like didn't even see who are my friends, Joe Moore: so, which Yeah. Joe Moore: Which is sad. That's like a subtext in, in like the notes coming away from 25. Is that the, um, American Right, if we wanna call it that, is very interested in this stuff. Oh yeah. Like the Texas establishment. Oh yeah. Um, the Texas contingent, right? They're deep. They're real deep. Mm-hmm. I have, um, Mary Carreon: let's talk about that more. Mary Carreon: Yeah. So Joe Moore: it's optimistic in, in some sense that psychedelic science is getting funded more. By states. 'cause the feds aren't stepping up. Right. I love that. Right. Yeah. Like, Hey feds, look what we can do. And you can't somehow, and [00:54:00] then, um, we'll see if state rights stays around for a while longer, maybe, maybe not. Joe Moore: And then the other part is like, is there a slippery slope given the rhetoric around addiction and the rise in interest in iboga for compulsory addiction treatment with psychedelics or, or compulsory mental health treatments with psychedelics because of the recent, it's illegal to be a person without housing. Joe Moore: Um, and you're gonna get put in treatment. Mm. Like, that's now a thing. So like, I don't know, I don't think forced treatment's good at all. I, and I don't think like, um, like the data is something like 15% effective, maybe less. Right. Right. It's not a good use of money. I don't know. We're, let's, I. You can go there if you want, and riff on that, or if you wanna talk about like, Texas, um, Arizona more generally. Mary Carreon: Yeah. I mean, I will just say this, I also don't really believe that forced treatment is like good, you [00:55:00] know, data Joe Moore: says it's bad. Mary Carreon: Yeah. Yeah. I also, yeah, I mean, it's like, I don't know. Yeah, that's, it's complex. It's a complex issue. I also don't think it's good, but I also do think that we need a much better framework and foundation for like, if people do want the help, helping them get it. Mary Carreon: Much more easily and in a way that's going to be beneficial for them. Um, and I don't think that that system or that pathway currently exists as we saw in, uh, with, with, um, measure 1 0 9 and the failure of measure 1 0 9 or, or was it Measure 1 0 10, 1 10, measure one 10 in Oregon. Joe Moore: But did you see the response yesterday or two days ago? Joe Moore: No, I didn't. No, I didn't. I'll I'll send it to you later. Okay. So the university did the research, um, Portland State University did the research Yes. And said, Hey, look, there was actually 20 other things that were higher priority. Like that actually influenced this increase in overdoses, not our law. Mary Carreon: Right. Mary Carreon: Yes. It was really COVID for Okay. [00:56:00] Like for, yeah. Right. Absolutely. Also, there was not a. Like there was not a framework in place that allowed people to get off the street should they want to, or you know, like, like you just can't really have a, all drugs are legal, or small amounts of drugs are legal without also offering or creating a structure for people to get help. Mary Carreon: That, that's, you can't do one without the other. Unfortunately. That's just like a, that's faulty from the start. So that's all I'll really say about that. And I don't think that that had fully been implemented yet, even though it was something that wasn't ideal for the, um, for the, for the measure. And I believe it was measure one 10, not measure 1 0 9, to be clear. Mary Carreon: Measure one 10. Um, yes, but confirmed one 10 confirmed one 10, yes. Mm-hmm. Um, but yeah, uh, that's, you know, that's kind of what I'll say. That's what I'll, that's where I'll leave that portion. Mm-hmm. You know? Uh, but yeah, forced treatment. I don't know. [00:57:00] We can't be forcing, forcing people to do stuff like that. Mary Carreon: I don't know. It's not gonna, it's, yeah, it doesn't seem Joe Moore: very humane. Mary Carreon: Yeah. No. And it also probably isn't gonna work, so, Joe Moore: right. Like, if we're being conservative with money, like, I like tote, like to put on Republican boots once in a while and say like, what does this feel like? And then say like, okay, if we're trying to spend money smartly, like where do we actually get where we want to be? Joe Moore: And then sometimes I put on my cross and I'm like, okay, if I'm trying to be Christian, like where is the most, like, what is the most Christian behavior here in terms of like, what would the, you know, buddy Jesus want to do? And I'm just like, okay, cool. Like, that doesn't seem right. Like those things don't seem to align. Joe Moore: And when we can find like compassionate and efficient things, like isn't that the path? Um, Mary Carreon: compassionate and t. Yeah, even, I don't know, I don't know if it looks lefty these days, but Yeah, I know what you mean. Yeah, I know what you mean. I know what you mean. Yeah. [00:58:00] Yeah. Um, yeah, it's complicated. It's complicated, you know, but going back, kind of, kind of pivoting and going back to what you were talking about in regards to the subtext, some of the subtext of like, you know, where psychedelic medicine is currently getting its most funding. Mary Carreon: You know, I do believe that that was an undercurrent at psychedelic science. It was the, the iboga conversation. And there's, there's a lot, there's a lot happening with the Iboga conversation and the Iboga conversation and, um, I am really trying to be open to listening to everyone's messages that are currently involved in. Mary Carreon: That rise of that medicine right now? Um, obviously, yeah, we will see, we'll see how it goes. There's obviously a lot of people who believe that this is not the right move, uh, just because there's been no discussions with, uh, the Wii people of West Africa and, you know, because of [00:59:00] that, like we are not talking to the indigenous people about how we are using their medicine, um, or medicine that does like that comes from, that comes from Africa. Mary Carreon: Um, also with that, I know that there is a massive just devastating opioid crisis here that we need to do something about and drug crisis that we need to be helping with. And this medicine is something that can really, really, really help. Um, I find it absolutely fascinating that the right is the most interested party in moving all of this forward, like psychedelic medicine forward. Mary Carreon: And I, I currently have my popcorn and I am watching and I am eating it, and I am going to witness whatever goes down. Um, but I'm, I, I hope that, uh, things are moving in a way that is going to be beneficial for the people and also not completely leave behind the indigenous communities where this medicine comes from. Joe Moore: [01:00:00] Mm-hmm. Mary Carreon: We'll see how it goes. Yeah. We'll see how it goes. We'll see how it goes. It Joe Moore: would be lovely if we can figure it out. Um, I know, and I think, uh, Lucy Walker has a film coming out on Iboga. Mm. I got to see it at Aspen, um, symposium last summer, and it was really good. Mm. So I'm sure it'll be cut different, but it's so good and it tells that story. Joe Moore: Okay. Um, in a helpful way. I'm gonna, I, yeah. I always say I'm gonna do this. I'm like, if I have space, maybe I'll be able to email her and see if we can screen it in Colorado. But it's like a brilliant film. Yeah. Cool. This whole reciprocity conversation is interesting and challenging. And so challenging being one of the few countries that did not sign onto the Nagoya protocol. Joe Moore: Absolutely. We're not legally bound, you know, some countries are Mary Carreon: I know. Yes, yes, yes. So Joe Moore: we're, you know, how do we do that? How do we do that skillfully? We still haven't done it with, um, first Nations folks around their [01:01:00] substances. Um, I think mushrooms are a little flexible and account of them being global, um, from Africa to Ireland and beyond. Joe Moore: And, but you know, that's, we still want to give a nod to the people in Mexico for sure. Yeah, absolutely. Absolutely. Yeah. Um, yeah. Yeah, it's, I had some fun commentary there that I would love to flesh out someday. Uh, but yeah, it's not for today. Mary Carreon: Yeah, yeah, yeah. Um, there's, yeah, there's obviously, there's obviously a lot with the conversation of reciprocity here and, um, I know, I, I don't know. Mary Carreon: I, I, what I do know is that we need to be listening to the indigenous people, not just listening to them second, like secondhand or listening to them, uh, once we have moved something forward, like actually consulting with them as the process goes. And that, you know, the way that both parties move, indigenous folks and, uh, western folks move, uh, are at inherently different paces. Mary Carreon: And, [01:02:00] um, I just hope, and I wish, and I, I hope, I just hope that, uh, Western what, like the Western party, the western folks who are diving into these medicines. Slow the fuck down and listen and just are able to at least make one right move. Just one, just like you. Like it's, doesn't have to be this, it doesn't have to be that hard. Mary Carreon: Although the pace of capitalism usually propels, uh, the western folks at, at a much quicker rate than, u